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Introduction: Pharmacovigilance in Juvenile Idiopathic Arthritis Patients 
Treated with Biologic Agents and/or Methotrexate (Pharmachild) is an international 
registry involving 86 centres in 32 countries from the Paediatric Rheumatology 
INternational Trials Organisation (PRINTO)/ Paediatric Rheumatology European 
Society (PReS). The registry was set up in 2011 to evaluate long term safety and 
efficacy profile of immunosuppressive treatments in children with Juvenile 
Idiopathic Arthritis (JIA). 
Objectives: To present data coming from the Pharmachild/PRINTO registry 
and analyze infections, with a main focus on opportunistic, also evaluating the 
relationship between infections and biologic and synthetic Disease-Modifying Anti-
Rheumatic Drugs (DMARDs) in children affected by JIA.  
Methods: We provided descriptive statistics for demographic, clinical data, 
drug exposure, adverse events (AE) and events of special interest (ESI). Data from 
Pharmachild were combined with those coming from two national registries: 
BiKeR from Germany and the Swedish registry. The analysis was then focused on 
infections. A panel of specialists in infectious and rheumatologic diseases, 
identified as Safety Adjudication Committee (SAC), elaborated and approved by 
consensus, through three Delphi steps, a list of opportunistic pathogens for use in 
immunosuppressed children. Primary objective of the SAC was to adjudicate the 
infectious events encountered by the patients in Pharmachild with particular 
attention on opportunistic infections (OI).  
Results: Data from 8,274 patients were reported from the Pharmachild 
registry, and combined with those from 3,990 and 3,020 patients from the Germany 
and the Swedish registries, respectively, for a total of 15,284 patients. The main 
differences between Pharmachild and the other two registries were found in the age 
of onset, in the distribution of the different categories of AIG and in the use of 
biological drugs. The most frequently reported AE in Pharmachild resulted to be 
infections, adjudicated by the SAC mostly as common (88.4%). A high percentage 
(17.4%) of OI was reported. Among all infectious events, herpes zoster and 
mycobacterial infections were the most frequent. A list of OI in pediatrics was 
identified for subjects with JIA.  
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Conclusions: Registries represent a powerful tool to address important issues 
on safety in children with JIA treated with immunosuppressive therapy. Their value 
can be increased by combining individual patient data from different national and 
international registries. The analysis of the AE in JIA patients has showed that 







 The present thesis has been divided into 5 chapters. Except for chapter 3, all 
chapters correspond to papers recently published on pediatric rheumatology 
journals by Dr. Gabriella Giancane during her PhD course.  
 
 Chapter 1 and 2 describe the recent advances in different categories of 
juvenile idiopathic arthritis (JIA) in order to introduce the reader to the 
disease, its therapy and the possible safety implications for treatment. 
 
 Chapter 3 provides a general description of the Pharmachild registry. 
 
 Chapter 4 and 5 describe the results from the Pharmachild registry with a 











OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC 
ARTHRITIS 
ABSTRACT 
In the last two decades, the management of juvenile idiopathic arthritis (JIA) has 
been revolutionized by the increased tendency toward early aggressive 
interventions and the availability of the novel biologic medications. In 2017, three 
novel randomized controlled trials have evaluated the effectiveness and tolerability 
of golimumab and tocilizumab in polyarticular JIA, and have shown that the 
combination with methotrexate may increase and prolong the effect of intra-
articular corticosteroid injection in children with oligoarthritis. A more rational 
approach to the management of JIA is being fostered by the recent publication of 
therapeutic recommendations, consensus treatment plans and advice for the optimal 
care. A few months ago, an international consensus effort has led to the 
development of the recommendations for the treat-to-target in JIA. The application 
of this strategy in routine care may improve disease outcome. Because the potential 
of attaining inactive disease in children with JIA has increased markedly, there is an 
urgent need for randomized controlled trials, analyses of clinical datasets, and 
expert advice to guide discontinuation of medications once complete disease 





The term juvenile idiopathic arthritis (JIA) embraces a heterogeneous group of 
illnesses, all displaying joint inflammation, but with distinct clinical phenotypes, 
disease courses, outcomes, and presumably, genetic background and 
pathophysiology (1). The current disease classification, based on the criteria created 
by the Pediatric Task Force of the International League of Associations for 
Rheumatology (ILAR), outlines seven disease categories, defined on the basis of 
the clinical and laboratory features present in the first 6 months of illness (2). JIA is 
the most common rheumatic disease of childhood and a leading cause of acquired 
disability in the pediatric age group. 
In the past two decades, the management of JIA has been revolutionized by the 
tendency toward earlier introduction of methotrexate (MTX), the more widespread 
use of intra-articular corticosteroids (IACs), and, most importantly, the availability 
of biologic disease-modifying antirheumatic drugs (DMARDs) (3). This advance 
has made disease remission an achievable objective for most children with JIA. 
Complete disease control is regarded as the ideal therapeutic goal because its 
attainment was found to lead to better long-term outlook (4).  
In recent years, the information on the efficacy and safety of drug therapies for 
JIA has been enriched through the accomplishment of new randomized controlled 
trials (RCTs) of traditional medications and biologic DMARDs. In addition, a more 
rational therapeutic approach has been fostered by the promulgation of therapeutic 
recommendations and consensus treatment plans. Most recently, a multinational 
collaborative effort has led to develop the recommendations for the treat-to-target 
(T2T) strategy in JIA. There is currently an increasing interest for an international 
consensus and evidence-based information to establish the optimal time for 
discontinuation of medication therapies in children with JIA who achieve sustained 
clinical remission. 
The aim of the present review is to summarize the results of the RCTs 
conducted in the last year in oligoarticular and polyarticular JIA, to examine the 
therapeutic recommendations and consensus treatment plans proposed for the same 
disease subsets, and to discuss the rationale that underlies the implementation of the 
T2T strategy in JIA. In addition, the results of a recent survey aimed to assess the 
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attitudes and strategies of pediatric rheumatologists toward withdrawing 
medications in children with clinically inactive JIA are discussed. 
 
Recent therapeutic advances in oligoarticular and polyarticular juvenile 
idiopathic arthritis 
Oligoarthritis, which is defined as an arthritis that affects four or fewer joints 
during the first 6 months of illness, is the most common JIA category in Caucasian 
children in North America and Europe (5). Although articular damage and physical 
disability in oligoarthritis are generally less common and severe than those seen in 
other forms of JIA, children with this disease may develop significant 
musculoskeletal abnormalities, such as flexion contractures, valgus deformities, and 
localized disturbance of bone growth (1). Furthermore, a sizeable proportion of 
them experience a spread of joint disease over time (so-called extended 
oligoarthritis). In this subgroup, the prognosis is guarded (6,7).   
In contrast to the numerous RCTs that have been performed in polyarticular 
and systemic JIA (3), only a few evidence-based data are available to guide the 
treatment of oligoarthritis (8–11). As a result, the management of this condition is 
largely empirical and likely variable among pediatric rheumatologists (12). 
IAC injections are widely used in the treatment of children with oligoarthritis 
(13). However, the role of methotrexate (MTX), which is a key medication in the 
therapeutic regimen of polyarticular JIA, in this disease subset are still unclear. 
Ravelli and co-workers (14) addressed the question of whether the concomitant 
administration of MTX to children with oligoarticular JIA who undergo IAC 
therapy augments the frequency and duration of remission of joint disease. This 
multicenter RCT conducted in Italy compared IAC injections alone versus IAC 
injections plus oral MTX in children with oligoarticular JIA. Although in the 
intention-to-treat analysis of the primary outcome (remission of arthritis symptoms 
in all injected joints at 12 months) the difference between the two therapeutic 
groups was not significant, post-hoc multivariable analysis and Cox proportional 
hazards model suggested that concomitant administration of MTX may prolong 
and, to a lesser extent, augment the effectiveness of IAC therapy. The assessment of 
safety did not show an appreciable increase in serious toxicity. 
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The results of this study suggest that, owing to its high remitting potential, the 
combination of IAC injections and MTX could play a major role in T2T strategies 
for children with chronic arthritis. An unexpected finding was that he addition of 
MTX did not reduce the prevalence of new-onset of arthritis in previously 
unaffected joints, which highlights the need of future studies aimed to scrutinize the 
capability of therapeutic interventions to prevent arthritis extension in children with 
oligoarticular-onset JIA.  
Previous RCTs have evaluated the efficacy and safety of three TNF inhibitors 
in polyarticular JIA: etanercept (15), infliximab (16) and adalimumab (17). 
Etanercept and adalimumab are presently licensed for use in JIA. A recent three-
part randomized double-blinded placebo-controlled withdrawal trial (GO-KIDS 
study) assessed a fourth TNF blocker, golimumab, in active polyarticular-course 
JIA (18). Golimumab is a fully human, anti-TNF-α monoclonal antibody that can 
be administered either intravenously or subcutaneously. The objectives of this study 
were to evaluate the efficacy, safety and pharmacokinetics of subcutaneous 
golimumab in children with active polyarticular JIA despite MTX therapy.  
During Part 1 (weeks 0–16), all patients received open-label golimumab (30 
mg/m
2
 of body surface area; maximum: 50 mg/dose) every 4 weeks, together with 
weekly MTX. Patients with at least 30% improvement per American College of 
Rheumatology (ACR) Pediatric (Pedi) 30 in Part 1 entered the double-blinded Part 
2 (weeks 16–48), after 1:1 randomization, to continue golimumab or switch to 
placebo. In Part 3, golimumab was continued or could be restarted as in Part 1. The 
primary outcome was disease flares in Part 2; secondary outcomes included ACR 
Pedi 50,70 and 90 responses, clinical remission, PK and safety.  
Of the 173 patients enrolled, 89.0% had an ACR Pedi 30 response and 79.2%, 
65.9% and 36.4% demonstrated ACR Pedi 50, 70 and 90 responses, respectively, in 
Part 1. At week 48, the primary endpoint was not met as treatment groups had 
comparable frequency of disease flares (41% in the golimumab group vs 47% in the 
placebo group; p=0.41), and the rates of clinical remission were also comparable 
(12.8% in the golimumab group vs 11.8% in the placebo group). Frequency of 
adverse events and serious adverse events were similar in the treatment groups 
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during Part 2. Injection site reactions occurred in less than 1% of all injections. PK 
analysis revealed that the dosing of golimumab was correct. 
The authors concluded that although the primary endpoint was not met, 
golimumab led to quick and clinically relevant improvement that was maintained 
over time even in patients who received placebo after week 16, and was well 
tolerated. Possible explanations for the failure to meet the primary endpoint include 
the long half-life of golimumab could have led to carry-over effects, with sustained 
disease control in patients who received placebo in part 2 and consequent delayed 
flare events in the placebo group; the low inflammatory burden of the study 
population; and the mandatory MTX background therapy that might have helped 
maintain disease control. Despite these negative results, it is widely thought that 
golimumab is effective in chronic arthritis and should be added to the therapeutic 
armamentarium for children with JIA (19).  
Tocilizumab (TCZ) is a humanized, monoclonal, antihuman interleukin (IL)-6 
receptor (IL-6R) antibody that binds to membrane and soluble IL-6R, blocking IL-
6-mediated signaling (20,21). Two RCTs have shown that tocilizumab is 
efficacious and well tolerated in the management of children with systemic JIA 
(22,23).  
Brunner and colleagues evaluated the efficacy and safety of TCZ for the 
treatment of patients with polyarticular-course JIA (24). This three-part, 
randomized, placebo-controlled, double-blind withdrawal study (CHERISH) 
enrolled patients who had active disease for a minimum of 6 months and inadequate 
responses to MTX. Part 1 was a 16-week, active-treatment, open-label, lead-in 
period, during which patients whose body weight (BW) was ≥ 30 kg received TCZ 
8 mg/kg and patients weighting less than 30 kg were randomly assigned 1:1 to 
receive TCZ at 8 mg/kg or 10 mg/kg. The drug was administered intravenously 
every 4 weeks. At week 16, patients with at least ACR Pedi 30 response entered a 
24-week, double-blind part 2 after randomization 1:1 to placebo or TCZ (stratified 
by MTX and corticosteroid use) for evaluation of the primary end point, which was 
disease flare, compared with week 16. Patients flaring or completing part 2 were 
given open-label TCZ in the part 3 of the study (64 weeks).  
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Of the 188 patients who were entered in part 1, 15 (7.9%) did not achieve an 
ACR Pedi 30 response and were discontinued from the study. Of the 163 patients 
who entered part 2, the 82 received TCZ and 81 were switched to placebo. The 
primary endpoint at week 40 was met as there were significantly more disease flare 
in the placebo group that in patients remaining on TCZ (48.1% versus 25.6%; 
p=0.0024). At the end of part 2, 64.6% and 45.1% of patients receiving TCZ had 
ACR Pedi 70 and ACR Pedi 90 responses, respectively. Response rates were 
numerically lower among patients weighting less than 30 kg who received 8 mg/kg 
TCZ than in the other two groups. The rates per 100 patient-years of adverse events 
(AEs) and serious AEs (SAEs) were 480 and 12.5, respectively; infections were the 
most common SAE (4.9/100 patient-years).  
This study showed that TCZ at monthly dosing of 8 mm/kg in patients 
weighting 30 kg or more and 10 mg/kg in patients weighting less than 30 mg/kg 
provided sustained and clinically meaningful improvement for patients with 
polyarticular-course JIA. The frequency of neutropenia and the rate of serious 
infection were both lower than those observed in a previous trial of TCZ in 
systemic JIA (3.7% versus 16.9% and 4.9/100 patient-year versus 11.0/100 patient-
year, respectively) (23). An interesting observation of this study was that 
biological-naïve patients had a lower incidence of flare regardless of assignation to 
TCZ of placebo, which is in keeping with the notion that patients previously treated 
with biologic medications could be more treatment-resistant. Also importantly, 
concomitant MTX administration was associated with fewer flare episodes both in 
TCZ and placebo subgroups.  
 
Treatment recommendations and consensus treatment plans  
In 2011, the ACR published a set of recommendations aimed to assist 
physicians in selecting the safest and most effective treatment for JIA (25). These 
recommendations were created following the Research and 
Development/University of California at Los Angeles (RAND/UCLA) 
Appropriateness Method and in accordance to the principles of the Appraisal of 
Guidelines for Research and Evaluation instrument (AGREE; www. 
agreecollaboration.org). The therapeutic choices are based on a step-up approach, 
13 
 
which dictates the prescription of medications with greater potency once the 
preceding treatment has failed. Instead of considering the ILAR categories, children 
with JIA were grouped into individual „treatment groups‟. Recommendations were 
proposed for five treatment groups and were shaped according to the grade of 
disease activity and the presence of features of poor prognosis specific for each 
group (Tables 1 and 2). Three levels of disease activity were defined: low, 
moderate, and high. The state of inactive disease/clinical remission was not 
considered. Tapering or discontinuation of medications for patients with inactive 
disease was also not addressed. In addition to the recommendations regarding 
treatment effectiveness, guidance for the safety monitoring of the medications used 
in JIA was provided. (26) 
We provide herein a summary of the recommendations outlined for JIA 




Table 1. American College of Rheumatology Recommendations for the treatment 
of juvenile idiopathic arthritis: features of poor prognosis and disease activity for a 
history of arthritis of 4 or fewer joints (adapted from ref. (25)) 
 
FEATURES OF POOR PROGNOSIS (must satisfy 1) 
   -Arthritis of the hip or cervical spine 
   -Arthritis of the ankle or wrist AND marked or prolonged inflammatory marker   
elevation 
   -Radiographic damage (erosions or joint space narrowing by radiograph) 
DISEASE ACTIVITY LEVELS 
   Low disease activity (must satisfy all) 
      -1 or fewer active joints 
      -Erythrocyte sedimentation rate or C-reactive protein level normal 
      -Physician global assessment of overall disease activity <3 of 10 
      -Patient/parent global assessment of overall well-being <2 of 10 
   Moderate disease activity (does not satisfy criteria for low or high activity) 
      -1 or more features greater than low disease activity level AND fewer than 3 
features of high disease activity 
   High disease activity (must satisfy at least 3) 
      -2 or more active joints 
     -Erythrocyte sedimentation rate or C-reactive protein level greater than twice 
upper limit of normal 
      -Physician global assessment of overall disease activity ≥7 of 10 





Table 2. American College of Rheumatology Recommendations for the treatment 
of juvenile idiopathic arthritis: features of poor prognosis and disease activity for a 
history of arthritis of 5 or more joints (adapted from ref. (25)) 
 
FEATURES OF POOR PROGNOSIS (must satisfy 1) 
   -Arthritis of the hip or cervical spine 
   -Positive rheumatoid factor OR anti–cyclic citrullinated peptide antibodies 
   -Radiographic damage (erosions or joint space narrowing by radiograph) 
DISEASE ACTIVITY LEVELS 
   Low disease activity (must satisfy all) 
      -4 or fewer active joints 
      -Erythrocyte sedimentation rate or C-reactive protein level normal 
      -Physician global assessment of overall disease activity <4 of 10 
      -Patient/parent global assessment of overall well-being <2 of 10 
   Moderate disease activity (does not satisfy criteria for low or high activity) 
      -1 or more features greater than low disease activity level AND fewer than 3 
features of high disease activity 
   High disease activity (must satisfy at least 3) 
     - 8 or more active joints 
      -Erythrocyte sedimentation rate or C-reactive protein level greater than twice 
upper limit of normal 
      -Physician global assessment of overall disease activity ≥7 of 10 





History of arthritis of 4 or fewer joints  
First-line NSAID monotherapy was recommended as one treatment approach 
for patients with low disease activity, without joint contracture and without features 
of poor prognosis. However, continuation of NSAID monotherapy for more than 2 
months was felt inappropriate for patients with continued active arthritis, 
independently of poor prognostic features. 
IAC injections were recommended for all patients with active arthritis, 
irrespective of disease activity level, prognostic features, or joint contracture. 
Triamcinolone hexacetonide was indicated as the preparation of choice. A duration 
of clinical improvement shorter than 4 months after local injection therapy may 
prompt the escalation of systemic therapy. However, IAC injections that result in 
clinical improvement of arthritis for at least 4 months may be repeated as needed. 
Initiation of MTX was recommended as initial treatment for patients with high 
disease activity and features of poor prognosis. After a previous IAC injection, 
MTX start was recommended for patients with high disease activity without 
features of poor prognosis and for patients with moderate disease activity and 
features of poor prognosis. Following repeated IAC injections, initiation of MTX 
was recommended for patients with moderate disease activity without features of 
poor prognosis and for patients with low disease activity and features of poor 
prognosis. 
Initiation of a TNF inhibitor was recommended for patients who have received 
IAC injections and at least 3 months of MTX and have moderate or high disease 
activity and features of poor prognosis. Anti-TNF therapy was also recommended 
for patients who have received IAC injections and 6 months of MTX and have high 
disease activity without features of poor prognosis. 
 
History of arthritis of 5 or more joints  
The indication of NSAID monotherapy was uncertain for patients with active 
arthritis. Continuation of NSAID monotherapy for longer than 2 months was 




Initial MTX therapy was recommended for patients with high disease activity, 
irrespective of poor prognostic factors, and for patients with moderate disease 
activity and features of poor prognosis. Following approximately 1 month of 
NSAIDs, initiation of MTX was recommended for patients with low disease 
activity and features of poor prognosis. After 1 to 2 months of NSAIDs, initiation 
of MTX was recommended for patients with moderate disease activity without 
features of poor prognosis. 
The use of methotrexate is favored over that of leflunomide, owing to the 
greater general experience with methotrexate. Nevertheless, initiation of 
leflunomide was highlighted as suitable initial treatment approach for patients with 
high disease activity and features of poor prognosis. Following a brief trial of 
NSAIDs, initiation of leflunomide was recommended as one treatment approach for 
patients with high disease activity without features of poor prognosis and for 
patients with moderate disease activity with features of poor prognosis. 
Initiation of a TNF inhibitor was recommended for patients who have received 
MTX or leflunomide for 3 months and have moderate or high disease activity, 
irrespective of poor prognostic features. Anti-TNF therapy was also recommended 
for patients who have received MTX or leflunomide for 6 months and have low 
disease activity, irrespective of poor prognostic features. 
Switching from one TNF inhibitor to another was considered indicated for 
patients who have received the current TNFα inhibitor for 4 months and have 
moderate or high disease activity, irrespective of poor prognostic features. 
Switching to a TNF inhibitor was recommended as one treatment approach for 
patients who have received abatacept for 3 months and have high disease activity 
and features of poor prognosis and for patients who have received abatacept for 6 
months and have moderate or high disease activity, irrespective of prognostic 
features. 
Prescription of abatacept was recommended as one treatment approach for 
patients who have received a TNFα inhibitor for 4 months and have high disease 
activity, irrespective of features of poor prognosis, or moderate disease activity and 
features of poor prognosis. Introduction of abatacept was also considered suitable 
for patients who have received more than one TNF inhibitor sequentially and have 
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moderate or high disease activity, irrespective of poor prognostic features, or low 
disease activity with features of poor prognosis. 
Rituximab was recommended as one treatment approach for patients who have 
received a TNFα inhibitor and abatacept sequentially and have high disease 
activity, irrespective of poor prognostic features, or have moderate disease activity 
and features of poor prognosis. Rituximab was felt to be more appropriate for 
patients who are positive for rheumatoid factor than for patients who are not. 
Guidelines for the management of JIA were also promulgated by the German 
Society for Pediatric Rheumatology (27). In the paper that reports these guidelines, 
the authors emphasize the following differences with the ACR recommendations: 
1) The ACR recommendations advise an early aggressive therapeutic approach. For 
instance, they recommend MTX as first-line treatment for patients with 
oligoarthritis and high disease activity. The German experts felt that MTX could be 
recommended in oligoarthritis in case of insufficient therapeutic effect of prior 
treatment with NSAIDs and/or corticosteroids. 2) The ACR recommendation of use 
of TNF blockers as escalation therapy in selected patients with ≤ 4 affected joints is 
based on studies conducted in patients with polyarthritis or extended oligoarthritis 
and not supported by evidence that these medications are safe and efficacious in 
patients with persistent oligoarthritis. 3) The German experts considered a brief trial 
of local or systemic administration of corticosteroids plus NSAIDs as a suitable 
first-line treatment for patients with polyarthritis. In this disease subset, the ACR 
recommends initial MTX therapy irrespective of disease activity. 4) Consensus was 
reached among German investigators about the use of corticosteroids as bridging 
therapy until full onset of the therapeutic effect of DMARDs is seen. The ACR 
recommendations do not provide any guide about the use of systemic 
corticosteroids for patients with oligoarthritis and polyarthritis, but only for patients 
with systemic arthritis. 5) Non drug-based therapy, including physical and 
occupational therapy, surgical interventions and psychological support, are not 
covered by the ACR recommendations. 
In 2016, the Pediatric Committee of the Canadian Rheumatology Association 
published a Position Statement on the current management of JIA (28). Overall, the 
Canadian committee members endorsed the ACR recommendations for 
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pharmacologic management of JIA. In addition, they highlight the importance of 
exercise, physiotherapy and occupational therapy, discuss the role of imaging to 
monitor disease activity and damage, and incorporate the recommendations about 
uveitis screening and management. Notably, in the general treatment principles it is 
stated that the goal of treatment is to attain a state of inactive disease with full, 
pain-free function. 
In 2010, the British Society for Paediatric and Adolescent Rheumatology 
(BSPAR) published the Standards of Care for children and young people with JIA, 
which were aimed to help the pediatric rheumatology teams to improve the service 
they provide by formulating a statement of the minimum set of standards of care for 
children, adolescents, and young adults with JIA (29). This advocacy statement 
emphasizes the importance of empowering children and their caregivers, facilitating 
early detection of JIA, prompt referral to a team of health professionals who are 
expert in the diagnosis and management of childhood rheumatic diseases, prompt 
access to all appropriate pharmacologic and biologic therapies, and regular 
followup and monitoring. 
In 2014, the Childhood Arthritis and Rheumatology Research Alliance 
(CARRA) developed Consensus Treatment Plans (CTPs) for new-onset 
polyarticular JIA through a case-based survey administered to CARRA members. 
This survey identified significant variability among treatment approaches. Two 
face-to-face consensus conferences were carried out by employing a modified 
nominal group technique in order to define treatment strategies, operational case 
definition, endpoints and data elements to be collected. A core workgroup 
subsequently reviewed the relevant literature, refined plans and developed 
medication dosing and monitoring recommendations. The approved CTPs included 
a step-up plan (non-biologic DMARD followed by a biologic DMARD in case of 
inadequate response in 3-6 months), an early combination plan (non-biologic and 
biologic DMARD combined within a month of treatment initiation), and a biologic 
only plan (biologic DMARD started without initiation of non-biologic DMARD). 
These approaches were approved by 96% of the CARRA JIA Research Committee 
members attending the 2013 CARRA face-to-face meetings (30).  
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These plans were aimed to highlight the importance of a correct timing in the 
introduction of therapies, rather than to address the use of specific medications, 
with the ultimate goal of reducing variations in treatment choices. In addition, they 
provide advice about medication dosing and monitoring, including tapering of 
corticosteroids. A major point of discussion of the face-to-face meeting in 2013 was 
selection of the outcome to be used as primary endpoint and the time point of 
observation. In the end, an agreement was reached that the ACR Pedi 90 at 12 
months is a robust, meaningful and realistic outcome in order to compare the three 
treatment strategies. It was also established that radiographic progression is a key 
outcome measure and that radiographs of at least 1 affected joint should be 
obtained at baseline and on a yearly basis. 
Unlike the ACR recommendations, the CTPs were developed by sole expert 
consensus, are devoted only to treatment-naïve recent-onset patients, and reflect 
current therapeutic strategies used in polyarticular JIA instead of focusing on 
particular classes of medications.  
A recently accomplished European Union-funded initiative, named SHARE 
(Single Hub and Access Point for Pediatric Rheumatology in Europe, has 
developed consensus guidelines for the optimal care of pediatric rheumatic diseases 
in European countries whose publication is under way (31). 
 
Toward a treat-to-target strategy for JIA 
As stated above, owing to the recent therapeutic advances, the achievement of 
disease remission has become a realistic objective in the management of children 
with JIA. As a result, the therapeutic aims in pediatric rheumatology settings are 
being moved toward the attainment of an inactive disease status (32–37). However, 
only scarce information about the potential of contemporary therapies to lead to 
disease remission is available. Indeed, inactive disease has seldom been included as 
a primary endpoint in RCTs of synthetic or biologic DMARDs in JIA. In addition, 
the goal of achievement of disease remission has not been uniformly formulated in 
the aforementioned therapeutic recommendations or guidelines. Considering that 
disease remission is now attainable for many, if not most, patients with JIA, it has 
been suggested that future treatment guidelines should incorporate as overriding 
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goal the achievement of clinical remission or, at least, minimal disease activity 
(38,39).  
Studies in adult patients with rheumatoid arthritis (RA) have shown that the 
strategy of tight control, with frequent adjustments of therapy according to 
quantitative indices, leads to improved patient outcomes (40–42). As a 
consequence, the paradigm of explicitly defining a treatment target and applying 
tight control and necessary therapeutic adaptation to reach the target has been 
incorporated into the „treat-to-target‟ (T2T) recommendations for RA (43,44) and 
spondyloarthritis, comprising psoriatic arthritis (45,46). This principle has also 
been endorsed in the recommendations for the management of RA (47–50). 
In recent years, standardized and well validated quantitative clinical measures 
for JIA have been published. They include the ACR Pedi response criteria (51), the 
definitions of clinical inactive disease (32,34) and minimal (or low) disease activity 
(52), and the Juvenile Arthritis Disease Activity Score (JADAS) (53,54). Cut-offs 
in the JADAS that correspond to the states of inactive disease and low, moderate 
and high disease activity have been established  (55–57). The composition of the 
measures of inactive disease and low disease activity and the respective definitions 





Table 3. Criteria for clinical inactive disease and low (minimal) disease activity in JIA 
 Items included  




Requirements for classification as CID 
or LDA 
Criteria for CID         
   Wallace‟s preliminary 
criteria(34) 
X  X X X X
§
  Normal ESR/CRP and all other items at 
zero or not present 
   ACR preliminary criteria(32) X  X X X X
£
 X Normal ESR/CRP, morning stiffness 
≤15 min and all other items at zero or 
not present 
   JADAS criteria(55) X X X X    JADAS ≤ 1 
   cJADAS criteria(56) X X X     cJADAS ≤ 1 
Criteria for LDA         
   Magni-Manzoni criteria – 
Oligo(52) 
X  X     PGA ≤ 2.5, AJC = 0 
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   Magni-Manzoni criteria – 
Poly(52) 
X X X     PGA ≤ 3.4, Pa/PtGA ≤ 2.1, AJC ≤ 1
$
 
   JADAS criteria(55) X X X X    Oligoarticular course: JADAS ≤ 2.0 
Polyarticular course: JADAS ≤ 3.8 
   cJADAS criteria(56) X X X     Oligoarticular course: cJADAS ≤ 1.5 
Polyarticular course: cJADAS ≤ 2.5 
§
Inactive uveitis was not defined 
£
Inactive uveitis as defined by the Standardization of Uveitis Nomenclature working group 
$
In systemic arthritis, absence of systemic features is required 
ACR: American College of Rheumatology; AJC: active joint count; CID: clinical inactive disease; cJADAS: clinical JADAS; CRP: C-
reactive protein; ESR: erythrocyte sedimentation rate; JADAS: Juvenile Arthritis Disease Activity Score; JIA: juvenile idiopathic 
arthritis; LDA: low disease activity; PGA: physician‟s global assessment of overall disease activity; Oligo: persistent oligoarthritis; 







All these tools constitute suitable targets to implement therapeutic strategies 
aimed at tight disease control in pediatric rheumatology settings. Recently, the 
preliminary definition of inactive disease in JIA (32,34) has been used as primary 
outcome measure in a randomized, double-blind, placebo-controlled trial of two 
aggressive treatment strategies in children with early JIA (58). Recently, the 
importance of applying the T2T strategy in childhood arthritis has been 
emphasized, as this may lead to improve patient outcomes (59,60). However, this 
approach has not hitherto been implemented in routine management of JIA. 
In 2017, an international Task Force of expert pediatric rheumatologists was 
convened to discuss this issue and to reach a consensus on a set of 
recommendations aimed at defining a T2T strategy for JIA. This effort was 
preceded a comprehensive systematic literature review (SLR), which was aimed to 
provide for consensus on the definition of treatment targets.  
It was decided that the SLR should primarily explore the current evidence 
regarding the following aspects: whether the treat-to-target strategy is preferable to 
a non-steered management; the time that should be waited to escalate treatment in 
patients with active disease; the best tool to be used as target; the potential role of 
biomarkers in decision-making; the influence of disease duration and JIA 
heterogeneity on the strategy and choice of the target; the evidence that a longer 
time spent in inactive disease leads to better long-term outcome; the impact of treat-
to-target in terms of cost, safety and treatment burden; the effect of treat-to-target 
on co-morbidities, including uveitis, psoriasis, depression, infections and adverse 
events; the evidence that improved patient/parent understanding on the disease 
improves the outcome; and the impact of treat-to-target on functional status, health-
related quality of life and burden of disease on patient‟s family life.  
The results of the SLR were analyzed by the expert Task Force at a consensus 
conference, which was held in Munich, Germany on August 24-25. After extensive 
discussion, numerous amendments and repeated voting, the experts formulated a set 
of recommendations in line with the European League Against Rheumatism 
(EULAR) standardized operating procedures (61). The individual statements that 
received a positive vote by the qualified majority of the expert committee members 
were retained and constituted the overarching principles and recommendations that 
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will guide the implementation of the T2T in JIA. These recommendations are in 
progress of publication (Ravelli A et al, manuscript in preparation).  
 
Treatment discontinuation after disease remission 
As discussed above, owing to the current therapeutic progresses, a high 
percentage of patients achieves an inactive disease status with contemporary 
therapies. Once complete disease quiescence has been achieved, it would be 
desirable to discontinue ongoing treatment to avoid prolonged exposure of the child 
to the potential of adverse effects. This goal should be balanced with the risk of 
disease flare after withdrawal of therapy. However, currently no guidelines or 
recommendations are available concerning appropriate discontinuation of 
medications after attainment of inactive disease status. As a result, treatment 
practices vary widely and remain empiric and physician-dependent.  
Several studies have examined the effect of discontinuing treatment in children 
with JIA who had achieved a state of clinical remission (reviewed in (62)). Overall, 
the relapse rate after termination of both methotrexate and TNF antagonists was 
substantial. However, no consistent predictors of the risk of flare were identified.  
Horton and co-workers (63) recently surveyed the members of CARRA to gain 
insights into the attitudes and strategies of pediatric rheumatologists toward 
withdrawing medications in children with non-systemic JIA who had achieved 
clinically inactive disease. Of the 388 practitioners, 124 (32%) provided their feed-
back. As expected, there was marked variability in the approaches regarding when 
and how to withdraw medications. The most highly ranked factors in making 
decisions about drug discontinuation was duration of inactive disease, although this 
factor was valued less by more experienced physicians. Other reported factors were 
a history of drug toxicity, patient and family preferences, duration of JIA before 
inactive disease, failure of multiple prior synthetic or biologic DMARDs, presence 
of joint damage, a history of previous disease flare, and evidence of subclinical 
inflammation on imaging. The JIA category was also important, with diagnoses of 
pJIA RF+ and persistent oligoarthritis making respondents less likely and more 
likely, respectively, to stop medications.  
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About three-quarters of respondents would wait for a minimum of 6–12 
months of inactive disease before tapering or discontinuing medications, whereas 
about two-third would wait for at least 12 months. There was a wide variability in 
the policy for decreasing or stopping or decreasing MTX or biologic therapies. 
stopping MTX or biologics. For children receiving combined administration of 
MTX and biologics, most clinicians preferred to stop MTX first. 
Most respondents reported using imaging only seldom or sometimes to guide 
decision making, but most were also reluctant to withdraw medications in the 
presence of asymptomatic imaging abnormalities suggestive of subclinical 
inflammation. This likely reflected the uncertainty about the prognostic significance 
of the finding of subclinical synovitis on ultrasound and MRI in children with JIA 
in clinical remission (64).  
 
Conclusions 
In the last year, the therapeutic armamentarium for JIA has been enriched by 
the evaluation of the effectiveness and safety of two biologic DMARDs, 
golimumab and tocilizumab, in polyarthritis. In addition, evidence has been 
provided that the association with methotrexate may increase the effectiveness of 
IACs in children with oligoarthritis. Altogether, these RCTs provide the clinicians 
with adjunctive evidence-based information that may help to augment the 
likelihood of reaching the desired therapeutic objectives. 
A more rational approach to the management of JIA has been fostered by the 
publication of therapeutic recommendations, consensus treatment plans and advice 
for the best standard of care for children with JIA. These efforts offer a valuable 
platform to better harmonize the protocols for disease treatment and monitoring in 
pediatric rheumatology centers throughout the world.  
There is now compelling evidence that the incorporation of a T2T strategy may 
improve the outcomes in children with JIA. A recent international consensus effort 
has led to the promulgation of the recommendations for the implementation of the 
T2T approach in the management of JIA. The recommendations are primarily 
aimed at pediatric rheumatology practitioners and other health professionals 
involved in the care of patients with JIA. However, they will likely encounter the 
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interest of clinical trialists and regulators, owing to the increasing interest of 
pharmaceutic industries for strategic trials. Parents and patients are another 
important audience that should be informed on these statements and their potential 
role in preventing or minimizing damage and disability. 
There is now an intense debate regarding whether targeting therapy to 
biomarkers or imaging measures provides better outcomes compared to treating to 
clinical targets alone. The studies performed thus far on these alternative targets do 
not allow to state their superiority. However, it is anticipated that the T2T approach 
aimed at clinical, biomarker or imaging remission in JIA will constitute a major 
area for research in the upcoming future. 
Because the potential of attaining inactive disease in children with JIA has 
increased markedly, there is an urgent need for randomized controlled trials, 
analyses of clinical databases, and expert recommendations to guide 
discontinuation of medications once complete disease quiescence has been 
achieved. Another important matter for future studies is to identify predictors of 
disease flare after treatment discontinuation. Thus far, immunologic biomarkers, 
particularly the myeloid-related proteins MPR8/14, appear more promising than 
demographic and clinical parameters and ultrasound. However, well designed 
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SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS 
ABSTRACT 
Systemic juvenile idiopathic arthritis (sJIA) is the form of childhood arthritis 
whose treatment is most challenging. The demonstration of the prominent 
involvement of interleukin (IL)-1 in disease pathogenesis has provided the rationale 
for the treatment with biologic medications that antagonize this cytokine. The three 
IL-1 blockers that have been tested so far (anakinra, canakinumab and rilonacept) 
have all been proven effective and safe, although only canakinumab is currently 
approved for use in sJIA. The studies on IL-1 inhibition in sJIA published in the 
past few years suggest that children with fewer affected joints, higher neutrophil 
count, younger age at disease onset, shorter disease duration, or, possibly, higher 
ferritin level may respond better to anti-IL-1 treatment. In addition, it has been 
postulated that use of IL-1 blockade as first-line therapy may take advantage of a 
“window of opportunity”, in which disease pathophysiology can be altered to 
prevent the occurrence of chronic arthritis. In this review, we analyze the published 
literature on IL-1 inhibitors in sJIA and discuss the rationale underlying the use of 






Systemic juvenile idiopathic arthritis (sJIA) is the most severe form of 
childhood arthritis and the most difficult to treat. Until recently, sJIA was 
considered a therapeutic orphan, since the most effective treatment was 
corticosteroids, whose long-term administration is associated with a wide range of 
side effects, including an increased risk of vertebral fractures, cataracts, growth 
retardation, and susceptibility to infection. Traditional disease-modifying anti-
rheumatic drugs (DMARDs), such as methotrexate, have limited efficacy for the 
joint disease and virtually no impact on the systemic features. Poor responses have 
also been reported with the newer anti-tumor necrosis factor (TNF) agents (65–68), 
although these medications may be effective in the later afebrile disease phase, 
characterized by chronic arthritis (69,70). Recently, anti-TNF therapy was found to 
restore normal levels of vasculoprotective and proangiogenic endothelial progenitor 
cells in children with JIA (71). Several experimental studies have suggested a major 
pathogenetic role for cytokines such as interleukin (IL)-6 (72) and, more recently, 
IL-1 (73). These findings have opened the way to the successful treatment of sJIA 
with biologic agents that antagonize selectively these cytokines. 
In the present review, we provide a brief overview of the main clinical features 
of sJIA and summarize the recent advances in therapy with IL-1 inhibitors. 
 
Clinical characteristics of sJIA 
sJIA accounts for 5-15% of all children with chronic arthritis in Europe and 
North America and is rather distinct from the other forms of JIA, owing to the 
association of arthritis with a severe systemic illness (74,75). It is considered the 
childhood-onset equivalent of adult-onset Still‟s disease. Children with sJIA 
typically present with a quotidian, high-spiking fever, often accompanied by an 
erythematous, salmon pink, macular rash, which tends to be migratory and is 
strikingly evanescent. Myalgias and abdominal pain may be intense during fever 
peaks. Other systemic manifestations include diffuse lymphoadenopathy, 
hepatosplenomegaly, and serositis, especially pleuritis and pericarditis. Arthritis is 




during the disease course weeks, months, or, rarely, years after the occurrence of 
extra-articular symptoms. At disease presentation, particularly when arthritis is not 
yet present, children often require an accurate diagnostic work-up to exclude other 
potential diagnoses, such as infections and malignancy.  Characteristic laboratory 
features include anemia (usually hypochromic and microcytic), leukocytosis, 
thrombocytosis, elevated immunoglobulins, increased erythrocyte sedimentation 
rate (ESR) and C-reactive protein (CRP), and hypoalbuminemia. The International 
League for Associations of Rheumatology (ILAR) criteria for the classification of 
sJIA are shown in Table 1. 
 
Table 1. ILAR criteria for sJIA.  
 
Arthritis with, or preceded by, daily fever of at least 2 weeks‟ duration that is documented to 
be 
quotidian for at least 3 days, and accompanied by one or more of the following: 
1) evanescent, non-fixed, erythematous rash 
2) generalized lymphadenopathy  
3) hepatomegaly or splenomegaly 
4) pericarditis, pleuritis and/or peritonitis 
Exclusion criteria 
- Psoriasis or a history of psoriasis in patient or first-degree relative 
- Arthritis in HLA-B27–positive male > 6 years of age  
- HLA-B27 associated diseases such as ankylosing spondylitis, enthesitis-related arthritis, 
sacroiliitis with inflammatory bowel disease, reactive arthritis, or acute anterior uveitis; or 
history of these in a first-degree relative 
- Positive rheumatoid factor test on 2 occasions ≥ 3 months apart 
 





It has recently been argued that there are patients not classifiable as sJIA by 
current criteria who present with the same systemic features seen in classic sJIA, but 
never develop arthritis (74). The similarity of clinical manifestations suggest that 
their illness is closely related to sJIA, despite the absence of arthritis. This subgroup 
of patients, which nowadays lacks a taxonomic designation, would meet the criteria 
for adult-onset Still‟s disease, which do not require the presence of arthritis for 
diagnosis (76). These considerations have led to propose to include these patients in 
the sJIA category, and to rename sJIA as Still‟s disease in order to harmonize the 
terminology with that of the adult counterpart (77). A recent analysis of initial 
clinical features of 136 children with sJIA through a Web-based registry has shown 
that the ILAR criteria identified only 30% of sJIA patients at disease presentation 
(78).   
The course and prognosis of sJIA are variable (74,75). Around 40% of patients 
have a good long-term outcome, with a monocyclic course that enters a permanent 
remission with time. A small proportion of patients have an intermittent course, with 
relapses followed by periods of quiescence. In the remaining half of the patients, the 
disease pursues a more severe, persistent disease course. Among this unremitting 
subset, the sickest children have ongoing systemic symptoms, early destructive 
polyarthritis, growth failure, and are exposed to the serious side effects of 
corticosteroids. This particular disease phenotype represents the most disabling of 
all the different forms of JIA. 
Children with sJIA are uniquely susceptible to develop a potentially fatal 
complication known as macrophage activation syndrome (MAS). MAS is 
characterized by an overwhelming inflammatory reaction due to an uncontrolled and 
dysfunctional immune response involving the continued activation and expansion of 
T lymphocytes and macrophages, with resultant massive hypersecretion of 
proinflammatory cytokines (79,80). Distinctive clinical features of MAS are high, 
nonremitting fever, hepatosplenomegaly, generalized lymphadenopathy, central 
nervous system dysfunction, hemorrhagic manifestations, and, in its most extreme 
forms, multiorgan failure. Characteristic laboratory abnormalities include 
pancytopenia, increased levels of ferritin, liver enzymes, lactate dehydrogenase, 




and decreased fibrinogen levels. A characteristic histopathologic feature of MAS is 
the accumulation of well-differentiated macrophages exhibiting hemophagocytic 
activity in bone marrow biopsy specimens or aspirates (81). Although 
approximately 10% of sJIA patients develop overt MAS, up to 30% of children have 
evidence of subclinical MAS (82,83). MAS can result in progressive multi-organ 
failure and eventually a fatal outcome if unrecognized. Recent studies indicate a 
mortality rate of 8% (84,85). In 2016, classification criteria for MAS complicating 
sJIA have been published (Table 2). (86,87)  
 
Table 2. 2016 classification criteria of MAS. 
A febrile patient with known or suspected systemic juvenile idiopathic arthritis is classified as 
having macrophage activation syndrome if the following criteria are met: 
Ferritin > 684 ng/ml 
and any 2 of the following: 
Platelet count ≤ 181 x 10
9
/liter 
Aspartate aminotransferase > 48 units/liter 
Triglycerides > 156 mg/dl 
Fibrinogen ≤ 360 mg/dl 
 
Adapted from Ravelli A et al. Ann Rheum Dis 2016;75:481–489 and Arthritis 
Rheumatol 2016; 68: 566–76. 
Interleukin-1 inhibitors in the management of sJIA 
Anakinra  
The first observation of successful treatment of sJIA with IL-1 inhibition dates 
back to 2004, when a remarkable response to the recombinant interleukin (IL)-1 
receptor antagonist anakinra in two patients with severe and refractory disease 




In a landmark study published in 2005, Pascual et al (73) reported that the 
administration of anakinra to 9 children with active sJIA refractory to other 
therapies led to striking improvement in clinical symptoms and inflammatory 
markers. Seven patients achieved complete remission and the other 2 patients had a 
partial response. The rationale for the treatment was provided by the demonstration 
that patients‟ serum induced the transcription of innate immunity genes, included 
those of IL-1α and IL-1β, in healthy peripheral-blood mononuclear cells, and that 
patients‟ peripheral-blood mononuclear cells produced an excess of IL-1β upon 
activation.  
A less impressive effectiveness was seen in a French multicenter, randomized, 
double-blind, placebo-controlled trial (ANAJIS trial), whose primary outcome was 
the achievement of an American College of Rheumatology Pediatric (ACR Pedi) 30 
response at 1 month. At treatment endpoint, 8 of 12 patients (67%) in the anakinra 
group and only 1 of 12 patients (8%) in the placebo group were responders 
(p=0.003). However, no patient in both groups achieved a more robust 
improvement (i.e. a modified ACR Pedi 100 response). Furthermore, loss of 
response was observed in most patients over time. The authors attributed the 
frequent lack of sustained efficacy to the presence of severe polyarthritis and the 
absence of fever in most patients at enrolment, to the possible insufficient dosage in 
younger patients, and to the study design, which precluded the concomitant use of 
DMARDs and allowed early tapering of corticosteroids. Notably, a de novo type I 
interferon signature, which is not a feature of untreated sJIA, was induced in the 
majority of anakinra-treated patients, regardless of clinical response (89). 
That anakinra could be less effective on arthritis symptoms than on systemic 
and laboratory features of inflammation was highlighted in a retrospective study by 
Gattorno and colleagues (90). By examining the pattern of response to anakinra in 
22 children with sJIA, they identified two groups of patients: one group exhibited a 
dramatic response, with rapid improvement of arthritis and normalization of the 
CRP within the first week of treatment; the other group had no response or 
experienced only transient improvement of joint disease and CRP. The only 
difference between responders and nonresponders or incomplete responders was a 




group. In vitro secretion of IL-1β and IL-18 by patient monocytes was not increased 
and was independent of both treatment outcome and disease activity. Other case 
series published around the same time also showed remarkable benefit among many, 
but not all, users of anakinra(91–93). 
Recent observations suggest that initiation of anakinra early in the disease 
course may improve outcome. A multicenter retrospective cohort study of 46 
patients who had received anakinra as part of initial corticosteroid-sparing regimen 
showed that around 60%, including 8 of 10 receiving anakinra monotherapy, 
attained a complete response without escalation of therapy. Almost all patients had 
rapid improvements in fever and rash, whereas a slower response of arthritis to 
treatment was seen, with persistently active synovitis in 39% of patients at 1 month, 
27% of patients at 3 months, and 15% of patients at 6 months. Inflammatory 
markers normalized in most patients within one month. Evidence that early 
intervention with anakinra could prevent the development of persistent synovitis 
was obtained for 91% of 35 patients followed up for at least 6 months. Disease 
characteristics and treatment were similar in patients with partial or absent response 
and patients with complete response, except that that the former patients were 
markedly younger at disease onset (median age 5.2 years versus 10.2 years; P = 
0.004). Notably, however, the median peak ferritin level was higher in complete 
responders than in partial or nonresponders (3,008 ng/ml versus 1,329 ng/ml). 
Although the difference was not significant, perhaps owing to the small size of the 
study population, this observation suggests that patients with more prominent 
activation of the monocyte/macrophage system are more responsive to IL-1 
inhibition (94).  
Vastert and co-workers (95) conducted the first prospective study of the use of 
an IL-1 antagonist as first-line therapy in sJIA. They started anakinra in 20 patients 
with new-onset sJIA who were corticosteroid-naïve. At 3 months, 85% of patients 
achieved an adapted ACR Pedi 90 response or had inactive disease; 75% of patients 
achieved this response while receiving anakinra monotherapy. In the majority of 
responding patients (73%), treatment could be stopped within 1 year, with remission 
being preserved during follow-up. However, in around one third of patients, 




well as the myeloid-related proteins (MRP) S100A12 and S100A8/9 were found to 
be potential biomarkers for guiding the strategy of stopping treatment with IL-1 
inhibitors. 
A recent single-center experience with anakinra therapy in 25 patients with sJIA 
showed that 56% of patients attained inactive disease. The only baseline variable 
significantly associated with response was the time interval disease onset and 
treatment start, with earlier treatment being associated with better outcome. Once 
more, however, the median ferritin level tended to be higher in patients who reached 
inactive disease than in those who did not (1506 ng/ml versus 360 ng/ml). 
Importantly, the comparison of the dose administered with the ideal dose of 
anakinra in each individual patient did not show any relation with therapeutic 
response (96). 
In spite of the demonstrations of its effectiveness, anakinra is not currently 
registered for the treatment of sJIA. 
 
Canakinumab 
A preliminary phase II, multicenter, open-label study evaluated dosing, efficacy 
and safety of the fully human anti-IL-1β antibody canakinumab in 23 children with 
sJIA and active systemic features. This analysis showed that the administration of 4 
mg/kg was associated with rapid and sustained improvement in clinical response 
and enabled reduction or discontinuation of corticosteroids. In keeping with the 
findings of the aforementioned study by Gattorno et al (90), responders to 
canakinumab had fewer active joints and a higher white blood cell count at baseline 
than did nonresponders (97).  
The results of this pilot study provided the basis for performing two double-
blind placebo-controlled trials of canakinumab in a larger population of sJIA 
patients with active systemic features (98). In the first trial, 84% of patients 
receiving a single injection of canakinumab compared with only 10% of those 
receiving placebo achieved an ACR Pediatric 30 response with no fever (p<0.001). 
The frequency of inactive disease in the canakinumab group was as high as 33% 
after only 15 days. In the second trial, conducted with a withdrawal design, 73% of 




31% had inactive disease at the end of the open-label phase, after a median of 113 
days. In the randomized withdrawal phase, the frequency of flare was markedly 
lower in the canakinumab group than in the placebo group (74% of patients in the 
canakinumab group had no flare, versus 25% in the placebo group; P=0.003). At the 
end of the withdrawal phase, 62% of canakinumab-treated patients and 34% of 
patients in the placebo group had inactive disease. The average corticosteroid dose 
was reduced from 0.34 to 0.05 mg/kg/day and corticosteroids were discontinued in 
33% of patients. Medication safety was overall good, although infections were more 
frequent with canakinumab than with placebo and 7 patients had MAS.  
Canakinumab has been approved for the treatment for the treatment of active 
sJIA in children aged 2 years and older both in Europe and in the US. 
 
Rilonacept 
The efficacy and safety of the anti-IL-1 soluble decoy receptor protein, 
rilonacept, were evaluated in a pilot 3-phase trial consisting in a 23 months of open-
label treatment preceded by a 4-week, double-blind, placebo-controlled phase. 
Although no significant differences in efficacy were observed between the 
rilonacept- and placebo-treated patients during the initial double-blind phase, fever 
and rash completely resolved by month 3 in all patients during the open-label 
treatment period and did not recur. The adapted ACR Pedi 30, 50, and 70 response 
rates at 3 months were 78.3%, 60.9%, and 34.8%, respectively, and were generally 
maintained over the study duration. In addition to declines in high-sensitivity CRP, 
reductions were seen in the levels of MRP-8/MRP-14 and D-dimer. In 22 of 23 
patients, prednisone was tapered or discontinued. Treatment was not associated with 
serious adverse events (99). 
A larger 24-week randomized trial of the same agent in 71 children with active 
arthritis in ≥2 joints, which incorporated a 4-week double-blind placebo phase, 
found a shorter time to response in the rilonacept arm than in the placebo arm 
(P=0.007). In a secondary analysis, 57% of the patients in the rilonacept arm had a 
response at week 4 compared with 27% of the patients in the placebo arm 
(P=0.016). No statistically significant association was observed between a poorer 




duration. However, the median disease duration tended to shorter among patients 
who responded at week 4 compared to those who did not. The medication was 
generally well tolerated (100).  
Thus far, rilonacept has not been approved for use in children with sJIA. 
 
Open issues and future outlook 
The advent of biologic agents that specifically inhibit IL-1 has dramatically 
improved clinical outcomes for many children with sJIA and confirmed the 
pathogenic role of this cytokine in disease processes. The demonstration of the 
prominent involvement of IL-1, together with the lack of HLA associations and 
autoantibodies and the strong implication of cells of the innate immune system, has 
led to the suggestion that sJIA is a distinct disease entity, with more similarities 
with autoinflammatory syndromes than with classic autoimmune diseases (77,101–
103).  
However, not all patients respond to IL-1 blockade (89,90,92,104). The varying 
susceptibility to anti-IL-1 therapy may be explained by the heterogeneity of sJIA. 
The aforementioned analysis of the pattern of response to anakinra identified two 
patient subsets, one with dramatic response, similar to that observed in cryopirin-
associated autoinflammatory syndromes, and the other resistant or with an 
intermediate response. Patients responding to anti-IL-1 therapy had fewer affected 
joints and a higher neutrophil count (90). This observation has led to postulate that 
the group with bright response represents a separate entity in which 
autoinflammatory mechanisms play the leading pathogenetic role, whereas the 
group with more severe arthritis may also have autoimmune components (74). Other 
investigators have found evidence that anti-IL-1 treatment may be more effective for 
systemic features than for articular manifestations of the disease (99). However, in 
the canakinumab study, the response to treatment of children with polyarthritis was 
similar to those without polyarthritis. A differential therapeutic response based on 
the presence or absence of systemic features could not be evaluated in this trial 
because all children enrolled had ongoing fever (98). 
The heterogeneous nature of sJIA has been further highlighted by Shimizu and 




serum IL-6 and IL-18 levels: an IL-6 dominant and an IL-18 dominant. The IL-6-
dominant subset had a more severe polyarthritis and higher serum levels of matrix 
metalloproteinase (MMP-3), whereas the IL-18-dominant subset was more prone to 
develop MAS. Whether the differences in the predominant cytokine expression or in 
the susceptibility to anti-cytokine therapies dissect the spectrum of systemic JIA into 
clinically or pathogenetically distinct disease entities, remains to be established.  
As noticed above, the tendency for ferritin level to be higher in responders to 
anakinra in some series suggests that patients with more pronounced activation of 
the monocyte system, which may predispose them to the progression to overt MAS, 
may be more susceptible to benefit from IL-1 inhibition. This hypothesis is in 
keeping with the recent reports of the effectiveness of anakinra in cases of MAS 
refractory to conventional therapies (79). 
Another explanation for the inconsistent effectiveness of IL-1 inhibition could 
be the timing of therapy. Nearly all patients included in earlier open studies and in 
randomized clinical trials had long-standing disease and were still receiving 
systemic corticosteroids when treatment with IL-1 blocking agents was initiated. 
These characteristics may account for the partial or absent responses seen in a 
significant minority of patients. More favorable outcomes were obtained with the 
use of IL-blockade as first-line therapy, particularly in patients with new-onset 
disease and not yet exposed to corticosteroids or other DMARDs (94,95). Many 
patients achieved inactive disease rapidly and were able to stop anti-IL-1 therapy 
within one year, with sustained remission during follow-up (95). Of equal 
importance was the observation of a significant reduction in the proportion of 
children who developed the chronic polyarthritis manifestation of their disease (94).  
The differential clinical responses in early versus late disease, coupled with data 
from animal models, have led to theorize a biphasic model of sJIA, in which the 
disease begins with a highly inflammatory febrile phase that, in more than half of 
the patients, converts over time to an afebrile phase characterized by chronic 
arthritis. The predominance of innate immune mechanisms in the early systemic 
stage, as opposed to the involvement of autoreactive T cells in the later induction of 
chronic arthritis, would explain why antagonism of IL-1 in new-onset disease is 




later in the disease course. Thus, early treatment with IL-1 inhibitors may take 
advantage of this “window of opportunity”, in which disease pathophysiology can 
be altered to avoid the occurrence of chronic arthritis (106).  
However, although this hypothesis is logical and attractive, its clinical 
background should be regarded in the light of some caveats. Because around 40% of 
patients with sJIA have a monocyclic course with spontaneous remission, results of 
open studies on patients with early disease may be biased toward patients destined 
to a milder course. Conversely, most patients enrolled in clinical trials had already 
had years of disease and, therefore, are unlikely to include patients with a 
monophasic course. In addition, the majority of these patients had proven refractory 
to other therapies. Thus, the observed different efficacy of IL-1 blockade between 
early and established sJIA could simply reflect the fact that the latter patient subset 
may be more challenging to treat. Nevertheless, although the hypothesis of a 
window of opportunity is far from proven, it should become the focus of further 
research into the pathophysiology of sJIA and, possibly, the objective of further 
multicenter trials in large populations, ideally combined with biomarker analyses.  
Since there are now three IL-1 inhibitors on the market, the question arises 
about which of them is preferable. Not only they differ in the molecular structure, 
but the mechanism of action is slightly different: anakinra blocks both IL-1α and IL-
1β, canakinumab inhibits only IL-1β, and rilonacept binds IL-1α, IL-1β, and IL-1 
receptor antagonist. However, it is still unknown whether the different biding 
properties translate into differential clinical effects (107). Anakinra has been the first 
agent tested and is, thus, the one for which more experience has been gained 
(although it is not registered for the treatment of sJIA). It has a short half-life of 4-6 
hours, which is advantageous for handling a major adverse event and provides a 
greater flexibility for the management of a medical emergency like MAS. However, 
the need of daily subcutaneous administrations, which are often associated with 
injection site reactions, may make it difficult to conduct therapy over long-term, 
particularly in younger children (89,92). The longer half-life of canakinumab, which 
enables its administration every 4 weeks, together with its blockage limited to IL-1β, 
makes this medication potentially better accepted and tolerated. Rilonacept could 




biologic activity of canakinumab (236 days), which could be a disadvantage in the 
setting of a serious toxic effect. Importantly, significant responses to canakinumab 
and rilonacept were seen in many patients who had previously been treated with 
anakinra, which suggests that failure of one anti-IL-1 therapy does not necessarily 
preclude use of another (99). Last but not least, the issue of cost may have a major 
impact on the choice of a particular molecule. The dosage, route of administration 
and half-life of the IL-1 inhibitors used in the management of sJIA is reported in 
Table 3.  
 
Table 3. Characteristics of the IL-1 inhibitors used for the treatment of sJIA. 
 Dosage Route of administration Half-life 
Anakinra  1-4 mg/kg/day  Subcutaneous 4-6 hours 
Canakinumab ≥2 years: 4 mg/kg/dose q 
4 weeks  
Maximum dose: 300 mg 
Subcutaneous 23-26 days 
Rilonacept Starting dose 4.4 mg/kg, 
then 2.2 mg/kg/week 
Maximum loading dose: 
320 mg 
Maximum weekly dose: 
160 mg/week 
Subcutaneous One week 
 
Overall, all anti-IL-1 agents have proven safe and well tolerated. However, 
concerns have been raised regarding the risk of infection, neutropenia, and liver 
dysfunction (108–110). Furthermore, several instances of MAS during treatment 
with IL-1 inhibitors, some of which with a fatal outcome, have been seen in clinical 




same phenomenon was reported during treatment with the IL-6 blocker tocilizumab 
(112,113). As discussed elsewhere, the occurrence of MAS during treatment with 
medications that inhibit proinflammatory cytokines implicated in its pathogenesis is 
a paradoxical phenomenon. Possible explanations include the increased rate of 
infections (which, in turn, may trigger MAS) associated with biologic therapies or 
the induction of an imbalance between up- and down-regulation of the various 
molecules that are part of the cytokine network (79,84). However, these episodes of 
MAS often abated after increasing the dose of biologic medications, which suggests 
a lack of causality and a real associative relationship in only a few instances. 
Treatment targeting another cytokine implicated in the pathogenesis of sJIA, 
such as the IL-6 blocker tocilizumab, has also demonstrated efficacy in clinical trials 
(112,113). So far, however, there are no clinical data that allow either to compare 
the effectiveness and safety of IL-1 and IL-6 antagonists or to establish their relative 
indications in sJIA.  
Additional investigations are needed to define the exact role of the currently 
available agents in the management of sJIA. Future studies will likely optimize the 
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THE PHARMACHILD REGISTRY  
In order to establish the long-term safety and efficacy (response, joint erosion, 
damage, and treatment adherence) of biologic agents and MTX in JIA, i.e. the extent 
to which these drugs do more good than harm under the usual circumstances of 
healthcare practice in JIA, European Union supported in 2011 the project called 
“Pharmacovigilance in JIA patients treated with biologic agents and/or MTX” 
(Pharmachild), to implement an observational international registry including all 
children with JIA treated with any available MTX and biologic agents formulation.   
 
Rationale 
Aim of the project was to assess the long-term safety (primary goal) and 
effectiveness (magnitude of response, prevention or slowing of joint erosions, 
damage, and treatment adherence) of MTX and biologic agents in JIA.  
 
Hypothesis to be tested 
The overall hypothesis was to test whether biologic agents ± MTX were able to 
maintain an acceptable safety profile in the long term in children with different JIA 
categories while achieving clinical remission and prevent/stop joint erosion 
development over time 
 
Primary objectives of the project 
•To compare the long term incidence rates of emergent moderate, severe adverse  
  events (AEs) and serious A (SAE) observed in paediatric subjects with JIA  
•To assess the long-term efficacy (magnitude of response, prevention or slowing  
  of joint erosion and damage, and treatment adherence) of biologic agents ±  





To accomplish these objectives 3 different cohorts were established (treated with 
either MTX alone, biologics with or without concomitant MTX, or not treated with 
MTX or biologics). Patients either not receiving medication, or getting Non-Steroidal 
Anti-Rheumatic Drugs (NSAIDs) or intra-articular steroid injections were considered 
as control group.  
 
Secondary objectives 
• To identify predictors of safety (clinical or experimental, magnitude of response,  
   remission) 
• To assess potential risk factors (e.g. concomitant medications or diseases,   
   medical history etc), which may modify the safety profile of biologic agents and  
   MTX 
• To evaluate efficacy in the different JIA categories, in terms of individual JIA  
   core set variables, and using the ACR Paediatric 30, 50, 70, 90, 100 criteria for   
   improvement, as well as Juvenile Disease Activity Score (JADAS-10, 27,71)  
   and the achievement of clinical remission on and off medication as well as the  
   occurrence of disease flare during biologic agents and MTX treatment course  
   and after drug discontinuation, and the attainment of a status of minimal  
   disease activity (MDA) 
•  To assess the number of children in which a biologic agent is added to the  
   treatment 
• To evaluate the progression of wrist joint erosion over time and abnormal  
   growth/maturation in JIA subjects presenting a wrist involvement 




• Proportion of JIA paediatric subjects with biologic agents and MTX -emergent  
   moderate/severe and SAEs, referred as all moderate/severe AEs and SAEs  
   belonging but not limited to events of special interest (ESI) such as   




   infections, autoimmune events, cardiovascular events, central nervous system  
   involvement (e.g. optic neuritis, demyelinating disease), infertility,  




•Three to 10-year and longer probability of not experiencing AEs. 
• Incidence rate of biologic agents and MTX-emergent moderate/severe AEs and  
  SAEs in the 3 comparator groups. 
• Treatment adherence and reasons of treatment withdrawal/change (e.g. lack of  
   efficacy, AE and SAE or add-on therapy for inefficacy/intolerance, remission) 
• Time to flare (as per standard PRINTO flare definition) during biologic agents  
   and MTX treatment course and after biologic agents and MTX discontinuation. 
• Joint space erosion over time (if part of routine care) according to the Poznanski  
  score and erosion score according to the adapted versions of the Sharp/van der  
  Heijde score at months 12 and 24. 
• Baseline clinical and demographic predictors of safety (either clinically or  
   laboratory), response, remission. 
 
Study Design 
This is an international, multicentre, observational, safety and efficacy study 
aimed to collect prospective safety, tolerability, efficacy, and treatment adherence 
information on JIA subjects exposed to any biologic agents and MTX, according to 
local standard of practice.  
This is a non-interventional study, where the medicinal products are prescribed as 
per the investigator‟s decision. The assignment of the subject to a particular 
therapeutic strategy is not decided in advance by the study protocol, but falls within 
current practice and the prescription of the medicine is clearly separated from the 
decision to include the subject in the study. No additional diagnostic or monitoring 
procedures are applied to the subjects and epidemiological methods will be used for 






JIA (any ILAR category) after proper consent/assent. Two specific populations 
were enrolled: 
• Prevalent cases: all patients under treatment or previously treated with 
biologic agents ± MTX, MTX alone or biologic agents alone or treated only with 
NSAIDs and/or steroid injection at the time of the project start were revised 
retrospectively to estimate moderate moderate/severe AEs and SAEs. The same 
patients continued to be followed over time after proper written informed consent. 
• Incident cases: all cases newly treated with biologic agents ± MTX since the 
registry start. 
From a time perspective the data collected derived from: 
• Retrospective chart review of safety data 
o Step 1: A census (e.g. collection of patient identification number, age, JIA 
type and type of treatment) was required from each centre before retrospective chart 
review of safety data initiation to avoid selection biases (e.g. to have the proper 
denominator against which evaluating the successful data collection).  
o Step 2: Retrospective chart revision for the collection of moderate/severe 
AE and SAEs until the time of the last available visit. This retrospective chart review 
was considered successful if at least 70% of the patients listed in the census were 
retrieved. This step included also the integration in the Pharmachild project of data 
collected by other ongoing national registries (e.g. German, UK, French, Italian, USA 
etc).  
• Prospective safety/efficacy data collection. This group included patients 
newly treated with biologic agents ± MTX and patients already on treatment and still 
followed at the participating centres and identified with the retrospective chart review.  
 
Exposure 
a) Medicinal Product (biologic agents ±MTX): prescribed according to treating 
physician‟s decision. Dose, frequency and route of administration comply with local 




b) Co-medications: NSAIDs, systemic, intra-articular CS, and folic acid or its 
derivatives whose dose, frequency and route of administration comply with local 
standard of practice. 
 
Inclusion criteria 
• Signed written informed consent by subjects and /or parent or legally  
         acceptable representative  
• JIA (any ILAR category).  
• Subjects receiving biologic agents ± MTX, MTX alone, or NSAIDs and/or  
         steroid injections only as per physician discretion. 
 
Choice of the comparator group 
Three main groups of patients were identified, each one serving as comparator 
group for the remaining groups: 
1. JIA patients treated with biologic agent alone or MTX alone; 
2. JIA patients treated with a combination of biologic and MTX (including any 
other add on therapy e.g. cyclosporine, leflunomide etc); 
3. JIA patients treated only with NSAIDs and/or steroid injections with at least 
3 years follow-up. 
Group 1 and 2 mainly refer to children with polyarticular course JIA treated with 
MTX ± biologics, while group 3 refers to children with mostly oligoarticular 
persistent course who are usually NOT treated with second line agents and have a 
more benign course. The 3 groups of children constitute the ideal comparator groups 








PHARMACOVIGILANCE IN JUVENILE IDIOPATHIC ARTHRITIS 
PATIENTS TREATED WITH BIOLOGIC OR SYNTHETIC DRUGS: 
COMBINED DATA OF MORE THAN 15,000 PATIENTS FROM 
PHARMACHILD AND NATIONAL REGISTRIES. 
 
ABSTRACT 
Background: The availability of methotrexate (MTX) and the introduction of 
multiple biological agents have revolutionized the treatment of juvenile idiopathic 
arthritis (JIA). Several international and national drug registries have been 
implemented to monitor accurately the long-term safety/efficacy of these agents. This 
report aims to present the combined data coming from Pharmachild/PRINTO registry 
and the national registries from Germany (BiKeR) and Sweden. 
Methods: Descriptive statistics for demographic, clinical data, drug exposure, 
adverse events (AE) and events of special interest (ESI). For the Swedish register, AE 
data were not available.  
Results: A total of 15,284 patient‟s data were reported, 8,274 (54%) from the 
Pharmachild registry, 3,990 (26%) and 3,020 (20%) from the Germany and the 
Swedish registries, respectively. Pharmachild children showed a younger age (median 
of 5.4 years versus 7.6) at JIA onset and shorter disease duration at last available visit 
(5.3 versus 6.1-6.8) when compared to the other registries. The most frequent JIA 
category was the rheumatoid factor negative polyarthritis (range 24.6-29.9%). 
Methotrexate (61-84%) and etanercept (24%-61.8%) were the most frequently used 
synthetic and biologic disease-modifying anti-rheumatic drug (DMARD), 
respectively. There was a wide variability in glucocorticoid use (16.7-42.1%). Serious 
AE were present in 572 (6.9%) patients in Pharmachild versus 297 (7.4%) in BiKeR. 
Infection and infestations were the most frequent AE (29.4-30.1%) followed by 
gastrointestinal disorders (11.5-19.6 %). The most frequent ESI were infections (75.3-
89%). 
Conclusions: This manuscript is the first attempt to present a very large sample 




represents the first proposal for data merging as the most powerful tool for future 








Juvenile idiopathic arthritis (JIA)(1) is the most common chronic paediatric 
rheumatic disease and an important cause of short and long-term disability and quality 
of life impairment(2-8). Although none of the available drugs for JIA has a curative 
potential, prognosis has greatly improved as the result of substantial progress in 
disease management with the introduction of biologics. Despite the good efficacy 
results of all phase III trials on biologic agents, the long-term safety profile needs to 
be further characterized. For example spontaneous reporting from countries with low 
incidence of tuberculosis suggested that tuberculosis might be problematic in patients 
treated with biologics(9). In August 2009, the Food and Drug Administration (FDA) 
announced through a Boxed Warning that an increased risk of certain cancers in 
children might occur and labeling for the TNF blocker products was updated.(10-14) 
A Cochrane review from February 2011 compared the adverse events (AE) of 
biologics and concluded that there is an urgent need for more research regarding their 
long-term safety of different biologics.(15) The availability of a large observational 
international and national registry could enable clinicians and regulatory agencies to 
monitor properly the long-term or rare safety events and effectiveness of these agents 
in the relatively low prevalent JIA.  
The aim of this project is to presents the combined data of the 
“Pharmacovigilance in JIA patients treated with biologic agents and/or MTX” 
(Pharmachild) international registry and two consenting JIA national registries the 
“Biologics in Pediatric Rheumatology Registry” (BiKeR) from Germany and the JIA 
registry from Sweden. Secondary goal was to test a sharing system for future merging 




The Pharmachild registry 
Pharmachild is an observational international registry, started in 2011 with 




members of the Paediatric Rheumatology INternational Trials Organisation 
(PRINTO).(16) 
Inclusion criteria were children with JIA as per the International League of 
Associations for Rheumatology (ILAR) criteria(17) receiving biologics or other 
synthetic disease-modifying anti-rheumatic drugs (DMARDs), as per physician 
decision. The registry contains two specific populations. The first is a retrospective 
cohort of all patients under treatment or previously treated with DMARDs by one 
time clinical chart revision of safety events and complete drug exposure since disease 
onset to last available follow-up. The second is a prospective cohort including all 
cases newly treated DMARDs since the enrollment in the registry and cases still under 
treatment with any drug.To avoid selection biases each center performed a census for 
all the patients previously treated with DMARDs at that specific centre, used as the 
reference to evaluate the enrollment capability. In a second step, the center entered 
retrospective data, considered successful if they retrieved at least 70% of the patients 
listed in the census. Finally, in a third step, the prospective data collection started.  
Data collection included full and complete details for ILAR classification criteria, 
demographic, clinical and laboratory information, efficacy (only for the prospective 
cohort) and safety data on a long-term basis. Centers reported the whole drug 
exposure of the patient, with dates of start and discontinuation of the drug, dosages, 
route of administration, reasons for discontinuation and possible correlation with the 
AEs. All the AEs of at least moderate/severe/very severe intensity and serious AE, 
using the latest release of the Medical Dictionary for Regulatory Activities 
(MedDRA) dictionary were reported; mild intensity was reported only for those AE 
which did not resolve and require a follow-up report. Some AEs were classified as by 
consensus of PRINTO members as events of special interest (ESIs).  
Efficacy data were collected in the prospective cohort through the JIA core set 
measures with whole joint count,(18) the disease activity status measured through the 
Juvenile Arthritis Disease Activity Score (JADAS), the annual evaluation of damage 
through the Juvenile Arthritis Damage Index (JADI) (19) and of growth and pubertal 
development and key information on imaging and bio-specimen local collection. As 
patient reported outcome (PRO) families completed online the Juvenile Arthritis 




or in the hospital (on tablets or paper), in order to provide key notes to the treating 
physician before the clinical examination.  
The system also provided data on drug exposure and occurrence of AEs (Figure 
1) as a tool to discuss the health status of a patient with the family.  
 
Figure 1. Pharmachild graphical depiction over time of the key efficacy and 
safety data. Drug exposure and adverse events are represented in parallel to JADAS 
pattern. The excel sheet with all the data could be downloaded automatically by all 
participating centres. In the present picture an example of a patient from an Italian 









Data collection was performed online via the secured PRINTO website on a 
dedicated server with a username and timely password on an https encrypted 
platform. English was the official language used for all forms completed by the 
physicians, while the PRO were available in the appropriate language spoken by 
parents/patients. The web system was designed to be user-friendly, modular and 
upgradable. During the data entry, several hundreds of automatic checks were in 
place to ensure data quality and consistency. In particular, safety events were 
checked for accuracy by the PRINTO certified MedDRA coders, which could go 
back to the center with electronic query tickets in case of missing or unclear 
information (Figure 2). A designated pediatric rheumatologist acted as Medical 
Monitor (JS), by performed an electronic check and revision of the AEs and ESIs; 
in addition for some ESI (e.g. infection) adjudicating committees were in place. 
 
 









The BiKeR registry 
The BiKeR registry in Germany focused since 2001 on AE and efficacy data in 
patients treated with etanercept (ETN), the first biologic licensed in Germany.(21) 
Since then surveillance was extended to all biologics approved for JIA.(22-24) 
Information on biologics not approved for JIA was collected also for such patients 
who have been admitted for an approved biologic if patients were switched. The 
BiKeR registry is founded by pharmaceutical companies with independent bilateral 
contracts. BiKeR was approved by the ethics committee of the physician board 
Aerztekammer Nordrhein, Duesseldorf. BiKeR registry includes about 80 study 
sites and since its inception has followed more than 4000 patients in Germany and 
Austria aged 2 to 18 years, who meet the ILAR criteria for JIA. Written consent 
was obtained from patients and parents and repeated if patient became adult. Only 
pseudonymized data were collected.  
Patient demographic characteristics, disease history, and previous treatments 
are documented at the time of patient enrollment. Details about relevant treatment 
and reasons for discontinuation, concomitant therapy, disease activity and AE are 
prospectively collected using standard case report forms (CRFs) at the start of 
treatment, at months 3 and 6, and every 6 months thereafter. Safety was analyzed 
based on adverse event reporting. All reported AE defined as any untoward medical 
occurrence in a subject administered a pharmaceutical product, even without a 
causal relationship with the treatment, were analyzed. Serious AE and ESI were 
defined as in Pharmachild. On site monitoring is performed in selected larger 
centers covering about 80% of admitted patients. In 2005, the register was extended 
to include a control group of 1500 biologic-naive JIA patients who started with the 
synthetic DMARD such as MTX to enable comparison of patients exposed to 
biologics to unexposed JIA cohorts.(25;26) The “Juvenile arthritis MTX/Biologics 
long-term Observation” (JUMBO) was launched in 2007, to include also data on 
long-term safety after transition to adulthood. (27) Actually 3,990 patients are 







The Swedish registry 
In 2009, the Swedish JIA-registry begun to follow all children on biologics and 
later expanded to all patients treated with or without DMARDs. Reports from care 
givers, patients and medical records using JADAS, quality of life questionnaires 
and arthritis specific questions were included in the registry, that after 5 years, 
includes 1700 children (60% of the total JIA population and above 90 % of patients 
on cytokine modulators). Data on treatment, as well as disease course and efficacy 
were included, while data on safety were not available.(28)  
 
Statistics 
All registries and participating centers obtained approval from their respective 
ethics committee and obtained consent/assent based on national existing 
regulations. 
Pharmachild, BiKeR and the Swedish registries reported cumulative summary 
data into predefined spreadsheet in order to provide baseline descriptive statistics of 
demographic and clinical data. Safety data were available only for Pharmachild and 
BiKeR. ESI common to both registries are reported. 
For qualitative data, frequencies (%) were reported, while quantitative data 




 quartiles. No formal statistical 
comparisons were performed.  
 
Results 
Demographic characteristics and drug exposure 
In Pharmachild a total of 11,796 patients were registered in the census registry 
as of January 2017 from 98 PRINTO centres in 32 countries.  Clinical and safety 
data were provided for 8,274/11,796 (70.1%) patients belonging to 86 participating 
centres. Sixty/86 (61.2%) centres provided at least 70% safety data of their local 
JIA patients, with a median of 55 patients per centre. Prospective data were 
collected for a total of 3,070 patients.  
Table 1 reports the demographic and clinical data for a total of 15,284 patient‟s 
data, 8,274 (54.1%) from the Pharmachild registry, 3,990 (26.1%) from the German 




German and Swedish registries were not overlapping with those in Pharmachild 
since the registries were created in different periods and included data from 
different patients with the same disease. 
Patients coming from Pharmachild database showed a younger age (median of 
5.4 years versus 7.6) at onset and shorter disease duration (5.3 versus 6.1-6.8) at the 
last available follow up visit with respect to the other registries. BiKeR reported a 
lower median number of children per centre (10.5 versus 52-55.5). ANA positivity 
was higher in BiKeR and missing in the Swedish register.  
The JIA category distribution differed among registries, but the most frequent 
JIA category was the rheumatoid factor (RF) negative polyarthritis (range, 24.6%-
29.9%). Oligoarticular JIA was more frequent in the Swedish registry (49.6% 
versus about 30.5%-37.1% in the other two registries), while in BiKeR the 
frequencies of oligo- and poly-articular JIA RF negative were similar (about 30%); 
Pharmachild depicted a higher frequency of systemic JIA (11% versus 4.7-6-7% in 
the German and Swedish registry).  
 
Table 1. Demographic and clinical characteristics of the JIA patients from different 










N = 8,274 
BiKeR 
N = 3,990 
Sweden 
N = 3,020 
N of countries 32 2# 1 
N of centers 86 72 33 
No of patients per center 55.5 (17-124) 10.5 (3-39.8) 52 (31-78) 
Age at onset 5.4 (2.4-10.0) 7.6 (3.2-11.7) 7.6 (2.9-11.7)
1 
Age at JIA diagnosis 6.2 (2.8-10.9) - 8.3 (3.5-12.8)
2 
Disease duration at last visit 5.3 (2.7-8.8) 6.1 (3.5-9.5) 6.8 (4.3-10.1)
3 
Female 5584 (67.5%) 2670 (66.9%) 1989 (65.9%) 
Antinuclear antibodies  
(ANA)* 
1767 (21.4%) 1900 (47.6%) - 
ILAR JIA category  
4 5 
   Systemic  911 (11.0%) 267 (6.7%) 109 (4.7%) 
   Oligo 3071 (37.1%) 1215 (30.5%) 1148 (49.6%) 
      Oligo persistent  2011 (24.3%) 494 (12.4%) - 
      Oligo extended  1060 (12.8%) 721 (18.1%) - 
   Polyarticular RF-  2183 (26.4%) 1192 (29.9%) 568 (24.6%) 
   Polyarticular RF+  322 (3.9%) 243 (6.1%) 85 (3.7%) 
   Psoriatic arthritis 285 (3.4%) 296 (7.4%) 160 (6.9%) 
   Enthesitis related arthritis 924 (11.2%) 649 (16.3%) 185 (8.0%) 
   Undifferentiated arthritis 578 (7.0%) 127 (3.2%) 58 (2.5%) 
*ANA at least 2 consecutively positive determinations according to local standards 
# Germany and Austria 
1 data available for 2,477 subjects 2 data available for 2,197 subjects 
3 data available for 2,479 subjects 4 data available for 3,989 subjects 




Table 2 reports the number of patients who ever received a drug from onset to 
last available follow-up visit, with the corresponding days of drug exposure per 
medication from the first day of drug administration to the last available follow-up 
visit, excluding the days off therapy for any reason. 
There was a global trend to use MTX as a first-choice syntethic DMARD, and 
Etanercept as a first line biologic, but the Swedish registry used these drugs in a 
lower percentage of patients (MTX 61% versus about 84% in Pharmachild and 
BiKeR, Etanercept 24% versus 43.5% in Pharmachild and 61.8% in BiKeR). 
Despite the similar percentage of patients using these medications, children from 
BiKeR were exposed for a shorter period to the drugs compared to Pharmachild 
children, while the Swedish registry demonstrated a much longer drug exposure, 
with a wide range of variability among patients. Adalimumab, among the most 
frequently used biologics, was administered in a similar percentage of patients 
among all the three databases (about 21% patients). Systemic steroids were used in 
a similar percentage of patients and with the same drug exposure in BiKeR and 
Pharmachild, while the Swedish registry administered shorter cycles of steroids in a 
smaller number of patients (about 40% of patients in Pharmachild and BiKer versus 





Table 2. Number of patients who ever received a drug from onset to last available 
follow-up visit, with the corresponding days of drug exposure per medication from 
the first day of drug administration to the last available follow-up visit. Data are 




 quartiles of days 
of drug exposure.  
Drug Pharmachild 
N = 8,274 
Days of drug      
exposure 
BiKeR 
N = 3,990 
Days of drug 
exposure 
Sweden 
N = 3,020 
Days of drug 
exposure 




























































































































Overall, the German registry showed a higher incidence of AEs, but with lower 
intensity. In Pharmachild 1,599/8,274 (19.3%) patients reported at least one 
moderate AE compared to 1,747/3,999 AE of any intensity (43.8%) patients in 
BiKeR. Indeed when the AEs of at least moderate intensity were compared between 
the 2 registries, the differences were less pronounced (18.5% for Pharmachild 
versus 10.2% in BiKeR). Serious AEs were present in 572 (6.9%) patients in 
Pharmachild versus 297 (7.4%) in BiKeR. Among them 13 deaths were reported in 
Pharmachild, 3 in BiKeR mainly due to severe infections and/or malignancies. 
Table 3 reports a total of 5,173 AEs in Pharmachild and 5,013 in BiKeR, 
according to the MedDRA dictionary divided by system organ class (SOC). 
Infection and infestations resulted as the most frequent SOC in Pharmachild and 
BiKeR (29.4% versus 30.1% respectively) followed by gastrointestinal disorders 
(11.5% versus 19.6%) while all remaining SOCs occurred in less than 10% of the 
AE. In Pharmachild, more injuries, poisoning and complications, haematological, 
and hepatobiliary disorders were reported compared to BiKeR, which showed more 
investigations, general disorders and administration site conditions, neurological, 
and immune system disorders. The number of uveitis, included in “Eye disorders” 
category, resulted comparable in the two registries (5.2% versus 6.2% in 
Pharmachild and BiKeR, respectively). 
These results were confirmed also by analyzing the distribution of AEs 
separately for the retrospective and the prospective visits. We identified a total of 
1,050 AEs extracted from the prospective visits, and 4,123 events by the 
retrospective data, divided by SOC. In general, the hierarchy and frequency of AEs 
were similar, with Infections and Infestations being the most frequent events. 





Table 3. Total number of AE by MEDdra SOC ordered by decreasing frequencies. 
Data are absolute numbers and frequencies (%)  
 Pharmachild 
N = 5,173 
BiKeR 
N=5,013 
Infections and infestations 1523 (29.4%) 1509 (30.1%) 
Gastrointestinal disorders 595 (11.5%) 984 (19.6%) 
Injury, poisoning and procedural complications 325 (6.3%) 152 (3.1%) 
Blood and lymphatic system disorders 291 (5.6%) 99 (2%) 
Investigations 285 (5.5%) 377 (7.5%) 
Eye disorders  270 (5.2%) 309 (6.2%) 
Skin and subcutaneous tissue disorders 256 (4.9%)  217 (4.3%) 
General disorders and administration site conditions 245 (4.7%) 410 (8.2%) 
Hepatobiliary disorders 233 (4.5%) 24 (0.5%) 
Surgical and medical procedures 209 (4.1%) 98 (2%) 
Nervous system disorders 151 (2.9%) 227 (4.5%) 
Musculoskeletal and connective tissue disorders 147 (2.8%) 138 (2.7%) 
Respiratory, thoracic and mediastinal disorders 112 (2.2%) 50 (1%) 
Psychiatric disorders 105 (2.1%) 157 (3.1%) 
Endocrine disorders 104 (2.0%) 6 (0.1%) 




Renal and urinary disorders 66 (1.3%) 21 (0.4%) 
Immune system disorders 33 (0.6%) 77 (1.5%) 
Vascular disorders 30 (0.6%) 46 (0.9%) 
Reproductive system and breast disorders 26 (0.5%) 13 (0.3%) 
Congenital, familial and genetic disorders 22 (0.4%) 9 (0.2%) 
Cardiac disorders 19 (0.4%) 13 (0.3%) 
Neoplasms benign, malignant and unspecified (incl cysts 
and polyps) 
16 (0.3%) 29 (0.6%) 
Ear and labyrinth disorders 13 (0.3%) 7 (0.1%) 
Social circumstances 11 (0.2%) 0 






Table 4 reports details for the 2,022 and 1,697 common ESI in Pharmachild 
and BiKeR, respectively. The most frequent ESIs were infections, which resulted 
the most prevalent in both registries (75.3% versus 89% in Pharmachild and 
BiKeR, respectively), followed by blood cells related ESIs. In Pharmachild 
infusion/injection related reactions were more frequent than in BiKeR (10.8% 
versus 1.4%). 
There were 27 cases of tuberculosis reported in Pharmachild (52% from Asia, 
37% from Europe, 11% from America) and none in BiKeR, while all 
serious/targeted infections were 674 (33.3%) and 171 (10.1%), respectively. 17 
cases of tuberculosis were during biologic therapy, namely TNF inhibitors in 14 
patients. 
Few cases of malignancies were reported in a similar fashion in either 
registries. Beside the reported cases of haematological malignancies in Table 4, in 
Pharmachild we could observe 10 additional cases (neoplasm others), represented 
for one third by haemangioma, and with the remaining patients suffering from 
thyroid cancer, cervix neoplasm, skin tumors, breast fibroadenoma, colon adenoma 
and osteochondroma. The German registry reported in the same group similar 
malignancies, in particular of the genital apparatus (thyroid carcinoma, germ cell 





Table 4. Total number of ESI ordered by decreasing frequencies. Data are absolute 





Infections 1523 (75.3%) 1509 (89%) 
   Serious/targeted infections (Epstein‐
Barr virus, cytomegalovirus, papilloma 
virus, herpes zoster primary 
and reactivation, and opportunistic 
infections)  
674 (33.3%) 171 (10.1%) 
    Tuberculosis 27 (1,3%) 0 
   Other infections 822 (40.6%) 1338 (78.8%) 
Infusion/injection related reactions 218 (10.8%) 24 (1.4%) 
   Infusion related reaction 144 (7.1%) 11 (0.6%) 
   Injection related reaction 74 (3.7%) 13 (0.8%) 
Blood cells related ESI 188 (9.3%) 90 (5.3%) 
   Pancytopenia 6 (0.3%) 65 (3.8%) 
   Neutropenia 107 (5.3%) 14 (0.8%) 
   Macrophage activation syndrome 75 (3.7%) 11 (0.6%) 
   Aplastic anemia 0 0 








   Inflammatory Bowel Disease (IBD) 21 (1.1%) 23 (1.3) 
   Other autoimmune diseases excluding  
      IBD, uveitis and  demyelinisation  
      disorders 
18 (0.9%) 24 (1.4%) 
   Lupus erythematosus systemic/lupus- 
      like syndrome 
4 (0.2%) 1 (0.1%) 
   Optic neuritis 4 (0.2%) 0 
   Multiple sclerosis 2 (0.1%) 0 
   Demyelination 1 (0.05%) 2 (0.2%) 
Malignancies 16 (0.8%) 13 (0.8%) 
   Leukaemias 3 (0.1%) 2 (0.2%) 
   Lymphomas 2 (0.1%) 5 (0.3%) 
   Haematopoietic neoplasms (excluding  
   leukaemias and lymphomas) 
1 (0.05%) 2 (0.2%) 
   Neoplasm (other) 10 (0.5%) 4 (0.2%) 
Others ESI 27 (1.3%) 11 (0.6%) 








      perforation 
   Pregnancy 9 (0.4%) 7 (0.4%) 
   Congestive heart failure 1 (0.05%) 0 
 
Discussion 
Since the 1990s, when the first immunomodulatory products for rheumatic 
diseases were introduced, the benefits of synthetic and biologic DMARDs became 
clear in the management of JIA. However, safety information for JIA is currently 
mainly derived from phase III clinical trials and more recent registries and 
administrative claims. Therefore little information exists on the long-term safety of 
these agents. A great scientific debate regarding the safety of TNF-blockers started 
in 2009 which lead the FDA to issue a warning regarding a possible association 
between the use of TNF-blockers and the development of lymphoma and other 
cancers in children and young adults with JIA(29). Until now, the effect of 
biological therapies on the risk to develop cancer or other risks such as infections in 
JIA is still controversial,(30) owing to confounding factors such as the use of 
concomitant immunosuppressants. Literature has provided evidence that an 
increased risk of malignancy exists among children with JIA when compared to the 
general population, irrespective of medication use. Conversely, other studies have 
not confirmed these findings, highlighting the need of further studies to estimate 
more accurately this risk.(11;13;31;32) In order to address more reliably this and 
other safety concerns several methods for pharmacovigilance could be implemented 
spanning from the results of phase II-III clinical trials, to post-marketing passive 
reporting or from registries (non for profit or sponsored by pharmaceutical 
companies).(10;33) With this purpose, several registries have been created in the 




European countries and in North America initiated independent registries or 
registries in collaboration with pharmaceutical companies for the long-term 
evaluation of the safety and effectiveness mainly of biologic DMARDs.(26;28;33-
37) Other research groups have concentrated their effort on the analysis of 
insurance claims. (30;38) PRINTO implemented Pharmachild in order to guarantee 
a critical mass of patients‟ data and to provide systematically-obtained evidence for 
provision of reliable scientific data for health professionals and health authorities. 
Aiming to avoid overlapping of data collection and to find an agreement on the 
proper way to share common data, a considerable number of European pediatric 
rheumatology societies (e.g. in France, Netherlands, Spain, Czech Republic 
primarily) agreed to use Pharmachild as their primary resource for data collection.  
This manuscript is the first attempt to present a very large sample of data on 
JIA patients from different registries, providing an overview on the baseline 
characteristics from international and national registries. This analysis highlights 
some differences, but also similarities. An important difference that we could 
observe was the highest frequency of AEs in the German BiKeR registry, but 
associated with a lower intensity, which may reflect the different inclusion criteria 
of the two registries. Indeed, in Pharmachild, events of mild intensity, defined as 
transient or mild discomfort (<48 hours) and no medical intervention/therapy 
required are excluded. This difference is the trade-off implemented in Pharmachild 
in order to concentrate on more important safety events and facilitate data 
collection in the everyday busy clinical practice.  
Similarities among registries regarding therapies and AEs could be identified. 
MTX was the most used synthetic DMARD. Etanercept was the most frequently 
used biologic agent in all registries considered, followed by Adalimumab. Drug 
exposure differentiated the three databases, since in BiKeR it was lower for almost 
all the medications, while in the Swedish registry much longer and with a wider 
range of exposure variability, despite the similar disease duration. The relatively 
high rate of Etanercept use in the BiKeR registry might be explained by the fact 
that this registry originally started as a registry for this specific drug, when 
Etanercept was the only approved biological drug in pediatric rheumatology and 




recent years in BiKeR, Etanercept is the first biologic in about two thirds of patients 
with non-systemic JIA. Systemic steroids were used much less in Sweden and for 
shorter periods, maybe due to the lower incidence of systemic JIA. About ESIs, 
infections were the most common event in both Pharmachild and BiKeR registries, 
while malignancies were reported in a limited number of patients. The overall 
frequency of the different AEs and ESIs was similar between Pharmachild and 
BiKeR. The major difference when comparing Pharmachild to BiKeR were an 
higher frequency of tuberculosis infection and infusion/injection related reactions in 
the first for a possible interviewer bias elicited by the Pharmachild case report 
forms which explicitly focus the attention of the clinicians to these AEs. The 
difference in the rate of tuberculosis infections may also reflect a different risk 
among European countries, and the need of higher awareness of this problem in 
some regions. 
Next to reporting baseline data from a large sample of JIA patients, this study 
could not merge individual patient data because of the lack of homogeneous 
information. It can be seen therefore as a practical proposal for future studies that 
involve data merging. We propose for future studies a 3-step procedure. In step 1, 
the CRFs of the different registries should be compared to highlight the similarities 
and differences. Step 2 will verify the database technical characteristic (e.g. Sql 
server version 2005, Access 2010, etc) and the field coding (e.g. gender, int, 
1=male; 2= female, etc). The third step related to the individual patient‟s data 
merging. An excel spreadsheet with the data specifications related to a specific 
manuscript will be shared with the participating registries. Each registry will have 
to add its own data related to the project. The coordinator of the project will merge 
the individual patients‟ data after proper coding transformation. A census (e.g. few 
demographic data of all patients in the registry) will be provided by each registry as 
preliminary step to check for a potential selection bias. The coordinator will then 
prepare a further spreadsheet to highlight the important missing information (query 
log) to be solved in a timely manner in order to proceed with the manuscript final 
analysis and drafting. The entire procedure may meet some obstacles due to the 
lack of homogeneous information among registries and ethical and data protection 




methodology appears as a successful tool for future studies increasing the number 
of patients and data.  
A possible limitation to our study is that a relevant part of clinical information 
comes from retrospective data with no efficacy results available. Nevertheless, as 
pointed out in the additional table 1, retrospective data in Pharmachild were mostly 
overlapping to prospective data, thus supporting the validity of these safety 
findings. This limitation becomes crucial when we consider efficacy data, which 
can be provided only by the prospective analysis. For this reason further work in 
the future will be focused on these patients in order to advance the use of JIA drugs 
through the study of the Pharmachild population. Future analytical work will have 
also to report accumulated patient years of treatment for each of the registries. 
 
Conclusions 
This manuscript is the first attempt to present a very large sample of data on 
JIA patients from different national and international registries and represents the 
first proposal for sharing of data from national and international registries as the 
most powerful tool for future analysis of safety and effectiveness, with the aim to 
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ADJUDICATION OF INFECTIONS IN JUVENILE IDIOPATHIC 
ARTHRITIS PATIENTS TREATED WITH SYTHETIC AND BIOLOGIC 
DRUGS: AN EVIDENCE BASED EVALUATION FROM THE 
PHARMACHILD REGISTRY 
ABSTRACT 
Background: Pharmachild is a pharmacovigilance registry on children with 
juvenile idiopathic arthritis (JIA). Little evidence exists in literature about the 
relationship between JIA and opportunistic infections (OI).  
Objective: To analyse the OI in the Pharmachild population, through the work 
of an independent Safety Adjudication Committee (SAC). 
Methods: The SAC (3 pediatric rheumatologists and 2 pediatric infectious 
disease specialists) elaborated and approved by consensus a list of OI for use in 
immunosuppressed children. Through a 5 step-procedure, all the at least severe and 
serious infectious events encountered by the patients in the Pharmachild registry, 
were retrieved and evaluated by the SAC. A final evidence-based listing of 
opportunistic pathogens/infection presentations was provided. 
Results: We found 772 adverse events in 572 eligible patients, of which 335 as 
serious/severe/very severe non-OI and 437 as OI (any intensity or severity). 
682/772 (88.3%) were adjudicated as infections, 603 (88.4%) common and 119 
(17.4%) opportunistic. The SAC considered the treatment of infection appropriate 
in 77% of the cases, and the immunosuppressive therapy possibly related to the 
event in 76% of the cases. Herpes infection was the most frequent event, followed 
by mycobacterial infections. The role of the list in identifying OI in pediatrics was 
confirmed by the comparison with the events adjudicated by the panel.  
Conclusions: We found a significant number of OI in JIA patients on 
immunosuppressive therapy. The approved list on the definition of OI in JIA 
patients, created by consensus and validated on the Pharmachild patients, makes 







With the advent of biologic disease modifying anti rheumatic drugs 
(DMARDs), in a chronic condition like juvenile idiopathic arthritis (JIA), 
regulatory authorities such as the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) have demanded to pharmaceutical companies 
and clinical researchers to evaluate the long term safety of drugs used in children 
enrolled in phase II-III clinical trials.(1-16) Due to the limited number of patients 
enrolled in these trials, (17) clinical researchers have devoted their work to the 
implementation of national and international registries, (18-28) or to the analysis of 
insurance claim data (29-32). 
Children during their growth are subject to a natural higher rate of infections. 
Treatments in JIA with synthetic and biologic DMARDs are expected to increase 
the frequency of common infections and the risk of serious and opportunistic 
infections, (23;31-35) including especially tuberculosis in some geographic 
areas.(36;37;37;38) In order to tackle the long term safety and efficacy evaluations 
the Paediatric Rheumatology INternational Trials Organization (PRINTO) started 
in 2011 Pharmachild, an observational international registry, with European Union 
initial funding support, enrolling children internationally.(39;40) 
Recent literature seems to confirm the likely high incidence of infections 
among JIA patients treated with immunosuppressants,(21) but conclusive data are 
not yet available, and in particular little evidence exists about the role of JIA or its 
immunosuppressive therapy in acquiring opportunistic infections (OI). 
Several studies in literature have the objective to define and classify OI for 
example in HIV patients or in cancer (41-44), but Winthrop and colleagues (33) in 
2015 were the first to convene a consensus meeting to review the published 
literature, on clinical trials and postmarketing surveillance, on OI in patients with 
immune-mediated diseases treated with biologic DMARDs, in order to provide 
consensus recommendations for their evaluation in the context of clinical trials and 
observational studies. 
Primary objectives of this study were to derive a consensus based list of 




identifying OI through the evaluation of the infectious events reported in 
Pharmachild by an independent Safety Adjudication Committee (SAC).  
 
Patients and Methods 
Pharmachild 
Pharmacovigilance In Juvenile Idiopathic Arthritis Patients (Pharmachild) 
registry (project number 260353) involves 86 participating centres in 32 countries 
members of PRINTO (at www.printo.it) and the Paediatric Rheumatology 
European Society (PRES at www.pres.eu) with the aim to observe children with JIA 
to compare the long term incidence rates of moderate, severe, very severe adverse 
events (AE) and serious AE (SAE) and to assess the long-term efficacy of biologic 
and synthetic DMARDS in JIA. For the related details on this registry we refer to 
the recently published manuscript.(40) 
 
Study design 
The study was divided into 5 main steps (Supplementary Figure S1).  
 
Step 1. Provisional listing of opportunistic pathogens/infection presentations 
A study Steering Committee (SC) comprehended two PhD medical doctors 
(GG and JS), two certified Medical Dictionary for Regulatory Activities 
(MedDRA) coders (CP, LV), 3 biostatisticians (AP, FB, FB) and two Senior 
researchers (NW, NR).  
The SAC was organized as an independent group of 5 physicians: 2 pediatric 
infectious disease specialists (EC and AG) and 3 pediatric rheumatologists (GH, 
HIH, DL), who have experience and expertise in the diagnosis and treatment of 
children with infectious or rheumatic diseases.  
The SC starting point was the prior work by Winthrop et al,(33) an 
international consensus committee (infectious disease, public health and pulmonary 
physicians and rheumatologists) that through a systematic review in immune-




recommended a list of definite and probable OI. This list was discussed, modified 
and approved by the SAC by consensus, through three subsequent Delphi web 
rounds, with the final result of a list of opportunistic pathogens/presentations for 
use in immunosuppressed children with JIA. In the first round SAC members 
worked independently from each other, while at the second round they could revise 
the comments from the other members. Finally consensus was agreed through a 
dedicated teleconference (moderator NR).  
The SC then integrated the review of the literature with more recent evidence 
on OI in JIA (32;45;46) and prepared a provisional list of OI pathogens, then 
matched with the MedDRA Preferred Terms (PT) in order to properly retrieve cases 
in the Pharmachild database.  
 
Step 2: Retrieval of infections in Pharmachild  
For the Pharmachild study, the investigators reported online on the PRINTO 
database all AE from the disease onset to the last available follow-up visit. The 
MedDRA System Organ Class (SOC) “infections and infestations” was categorized 
in Pharmachild as Event of Special Interest (ESI), including two different groups of 
infectious events, classified as tuberculosis and targeted infections (Epstein‐Barr 
virus, cytomegalovirus, papilloma virus, herpes zoster primary and reactivation, 
and opportunistic infections). 
According to the Pharmachild protocol, all events (AEs and ESIs) of at least 
moderate intensity and all SAE were collected. AEs and ESIs were coded initially 
by the investigators during data entry using MedDRA dictionary, then recoded, if 
needed, by the PRINTO certified MedDRA coders and revised by the PRINTO 
medical monitor (JS), based on the most current version of MedDRA. All 
infectious events (both initial and follow-up) in the MedDRA system organ class 
(SOC) (Supplementary Figure S2) infection and infestations in Pharmachild at 







Step 3. Adjudication of infections by the SAC 
A standard operating procedure (SOP) described the work to be done by the 
SAC. In brief, inclusion criteria for the SAC adjudication process were all the 
opportunistic events in the provisional list of OI derived by step 1 (any grade of 
severity) plus the non-opportunistic infections of at least severe intensity or all 
serious infections.  
The list of the events to be adjudicated by the SAC was provided in a dedicated 
external area of the PRINTO/Pharmachild website, with access through secure 
personal username and password. 






The SAC members who revised all eligible cases presented in alphabetical 
order were blinded to the provisional list of opportunistic pathogens/presentations 
(see Step 1), and did not participate to data collection in Pharmachild. 
The full patients‟ data were available for the SAC members: 1. Demographic 
characteristics of the patient (with personal data encrypted); 2. ILAR category of 
JIA; 3. Laboratory and clinical information; 4. Complete drug therapy with whole 
drug exposure for synthetic and biologic DMARDs since disease onset to the last 
available observation; 5. Concurrent medications at the time of the infectious event; 
6. Full AE report plus ESI specific form for infections. In addition, disease activity 
and damage measure were available for prospective visits. The SAC members had 
the possibility to access clinical information in its entirety through a read-only 
modality with no possibility to modify the original data. A numeric code allowed 
the patient inclusion, without any patient or center identifier and no a priori 
categorization of AE as OI or serious were provided so to decrease the biases in 
their adjudication exercise. 
The SAC mandate was to evaluate each infectious case, based on the whole 
patient‟s history available in Pharmachild, by answering 5 questions: 1. Based on 
the information provided, do you confirm that this patient had an infection?; 2. Is 
this infection common?; 3. Is this an opportunistic infection?; 4. Was the treatment 
appropriate for the infection?; 5. Could the event be possibly related to any of the 
drug(s) taken at the time of the event? The study SC was available to provide any 
additional information related to the event and required by the SAC at any time. 
The consensus among the SAC members was defined as an agreement of at 
least 3 out of 5 (60%) members, on the first 3 out of 5 prior adjudication questions 
(“Is this an infection?”, “Is it common?”, “Is it opportunistic?”). Initially the SAC 
members worked independently from each other while in the second step for all 
cases without consensus each member could access the evaluations by the other 
SAC members.  
 
Step 4. Analysis of the Pharmachild registry 
Step 4 was designed to evaluate, in an evidence-based fashion, the frequency of 




among the SAC, and to assign a final MedDRA code (HLT/PT) to the event. In 
case of discrepancies in the categorization, after PRINTO and MM (JS) check, a 
third examiner (GG) re-evaluated the individual case to assign the final MedDRA 
code (HLT/PT). 
 
Step 5. Final evidence-based listing of opportunistic pathogens/infection 
presentations 
In this step all the infectious events adjudicated by the SAC in Pharmachild 
were matched by MedDRA PT term with the provisional list of OI (see Step 1) and 
divided in three groups: “confirmed OI”, whether there was full agreement between 
the SAC and the provisional list of OI; “confirmed non-OI” for those events 
adjudicated as non-OI by the SAC and missing in the provisional list; 
“possible/patient and/or pathogen related OI”, for the remaining events in 
Pharmachild that could be possibly considered opportunistic depending on the 
physician‟s evaluation of the patient history and by the detection of the specific 
pathogen causing the disease. 
 
Statistical analysis 
Descriptive statistics were reported in terms of absolute frequencies and 
percentages for qualitative data. Quantitative data were described in terms of 




Step 1. Provisional list of opportunistic pathogens/presentations 
After the three web Delphi rounds, the probable and definitive definitions of OI 
were agreed with one major change by 5/5 (100%) of the SAC. In particular, the 
definition of definite OI was confirmed, while for probable infections it was 
integrated with the following “In case of the unusually severe course of infection 




tentatively be considered opportunistic in a patient with impaired immune function. 
Two definite categories of pathogens/presentations were modified by the SAC, 
while twelve were added in the provisional list of probable OI from the literature 
and matched with the HLT/PT MedDRA dictionary; no infections already included 
in the list by Winthrop et al were deleted.  
Supplementary table S1 shows the provisional list of pathogens/presentations, 
with the corresponding HLT terms according to MedDRA dictionary. 
 
Step 2: Retrieval of infections in Pharmachild  
Among the 8,274 patients enrolled in the Pharmachild registry at January 2017, 
895 (10.8%) patients experienced 1,585 infections. A total of 772 events (48.7%) in 
572 patients were eligible for the evaluation by the SAC, of which 437 resulted as 
preliminary OI and 335 as very severe/severe or serious non-OI affecting (Figure 
1). The baseline characteristics of the 572/895 (63.9%) adjudicated patients are 
reported in Table 1 in comparison with those who were not adjudicated ones. The 
adjudicated group was represented by younger patients, with longer disease 






Table 1. Demographic and clinical characteristic of the Pharmachild patients with 
infections evaluated or not evaluated by Safety Adjudication Committee (SAC). 
Data are n (%) or medians (m) with IQR range. Drugs refers to their administration 















Females  388 (67.8%) 241 (74.6%) 629 (70.3%) 
Age at  onset ,  m 3.1 (1.7-6.7) 4.1 (2.1-8.5) 3.5 (1.9-7.3) 
Age at  diagnos is ,  m 3.7 (2.1-7.5) 4.9 (2.4-9.5) 4.1 (2.2-8.1) 
Disease duration at     
last  follow-up,  m 
7.6 (5.0-11.1) 5.8 (3.1-10.3) 7.1 (4.2-10.8) 
JIA category     
Systemic  120 (20.9%) 37 (11.4%) 157 (17.5%) 
Oligo pers istent  101 (17.7%) 80 (24.8%) 181 (20.2%) 
Oligo extended  100 (17.5%) 50 (15.5%) 150 (16.8%) 
Polyar ticu lar  RF- 132 (23.1%) 84 (26.0%) 216 (24.1%) 
Polyar ticu lar  RF+ 19 (3.3%) 15 (4.6%) 34 (3.8%) 
Psoriatic  25 (4.4%) 8 (2.5%) 33 (3.7%) 
Enthes it is  36 (6.3%) 21 (6.5%) 57 (6.4%) 
Undiffer entiated 39 (6.8%) 28 (8.7%) 67 (7.5%) 
Therapy    
Systemic glucocorticoids 336 (58.7%) 490 (54.7%) 154 (47.7%) 
Synthetic DMARDs    
Methotrexate 532 (93.0%) 821 (91.7%) 289 (89.5%) 
Cyclosporine 90 (15.7%) 103 (11.5%) 13 (4.1%) 
Sulfasalazine 66 (11.5%) 94 (10.5%) 28 (8.7%) 
Leflunomide 40 (7.0%) 68 (7.6%) 28 (8.7%) 
Azathioprine 17 (3.0%) 23 (2.6%) 6 (1.9%) 
















Thalidomide 7 (1.2%) 9 (1.0%) 2 (0.6%) 
Biologic DMARDs    
Etanercept 298 (52.1%) 424 (47.4%) 126 (39.0%) 
Adalimumab 178 (31.1%) 260 (29.1%) 82 (25.4%) 
Tocilizumab 103 (18.0%) 122 (13.6%) 19 (5.9%) 
Infliximab 84 (14.7%) 101 (11.3%) 17 (5.3%) 
Anakinra 54 (9.4%) 82 (9.2%) 28 (8.7%) 
Abatacept 39 (6.8%) 56 (6.3%) 17 (5.3%) 
Canakinumab 28 (4.9%) 38 (4.2%) 10 (3.1%) 
Rituximab 26 (4.5%) 29 (3.2%) 3 (0.9%) 
Golimumab 14 (2.4%) 20 (2.2%) 6 (1.9%) 
Certolizumab 4 (0.7%) 5 (0.6%) 1 (0.3%) 
Other biologic agents 2 (0.3%) 3 (0.3%) 1 (0.3%) 
 
Step 3. Adjudication of infections by the SAC 
A total of 689/772 (89.2%) events achieved consensus (3/5 SAC members) on 
the first 3 adjudication questions and, of these, 682 (99.0%) were considered as 
infections by the SAC (Table 2). The majority of the infections were considered 
common (88.4%) with 119 infections (17.4%) classified as opportunistic by the 
SAC after evaluation of the whole patient‟s history. The last 2 questions were more 
difficult for consensus to be reached. Regarding the fourth question, about the 
appropriateness of the treatment for the infection, consensus was achieved for 484 
(77.1%) events, while for 140 (22.3%) of the cases it was impossible to determine 
the suitability of the infection treatment.  
Similarly for the fifth question about the possible relationship between the 
infection and the related JIA treatment(s), the lack of consensus increased up to 279 
(41%). For 307/403 (76.2%) cases for which there was consensus, the SAC 
considered the drug(s) possibly related to the event. The administration of 1 




was the most frequent association with infection (32% of the cases), followed by 
methotrexate alone (21%), etanercept alone (20.3%) and finally by the association 
of either 1 biologic plus 1 synthetic DMARD plus systemic steroids (9%) or 1 





Table 2.  Frequency of answers by the SAC. Consensus by the majority of the SAC members (3/5) was required on the first 3 
questions. SAC: Safety Adjudication Committee. ID: impossible to determine. 
 
Questions for the SAC adjudication  Yes No ID Events with 
consensus 
1. Based on the information provided, do you 
confirm that this patient had an infection? 
682 (99%) 0 7 (1%) 689 (100%) 
2. Is this infection common? 603 (88.4%) 78 (11.4%) 1 (0.2%) 682 (100%) 
3. Is this an opportunistic infection? 119 (17.4%) 556 (81.5%) 7 (1%) 682 (100%) 
4. Was the treatment appropriate for the 
infection? 
484 (77.1%) 4 (0.6%) 140 (22.3%) 628 (92%) 
5. Could the event be possibly related to any of 












Step 4. Analysis of the infections according to MedDRA dictionary 
The evaluation of the Pharmachild registry conducted by the SAC led to the 
adjudication of the 682 infections corresponding to 53 HLT and 153 PT. For 92 
(60%) PTs, the SAC confirmed the same PT used by the Pharmachild Medical 
Monitor, while for the remaining 40% discrepancies were solved by the study SC 
after re-evaluation of the individual cases. The final number of HLT was 50, with 
corresponding 149 PTs, showed in details with the frequency of the events in 
Supplementary Table S2. 
 
Step 5. Final evidence-based listing of opportunistic pathogens/infection 
presentations 
After matching the adjudicated events with the provisional list of OI, among 
the 682 events, 106 (15.5%) for 22 PT were classified as “confirmed OI”, 274 
(40.2%) for 89 PT were classified as “confirmed non-OI”, and 302 (44.3 %) for 38 
PT were classified as “possible/patient and/or pathogen- related OI”.  
Table 3 shows the frequency of the “confirmed OI” by HLT/PT. Regarding 
pathogens, herpes viral infections resulted the most represented HLT/PT category, 
with 72 events (68% of the total confirmed OI), mostly represented by herpes zoster 
infection (66/72, 91.6%). Tuberculosis, Candida, Papilloma and Pneumocystis 
followed with a frequency higher than 3% among “confirmed OI”. Of the total 29 
tubercular infections in Pharmachild (Supplementary table S2), only 11/106 














Table 3. Frequency of the 106 infections “confirmed OI” adjudicated by the SAC 
after evaluation of the cases available in Pharmachild with full agreement between 
the SAC and the list of provisional pathogens/presentations.  Data are presented as 








Herpes viral infections 72 (68%) 
Herpes zoster 66 (91.6%) 
Herpes ophthalmic 2 (2.8%) 
Ophthalmic herpes zoster 2 (2.8%) 
Herpes virus infection 1 (1.4%) 
Herpes zoster oticus 1 (1.4%) 
Tuberculous infections 11 (10.4%) 
Pulmonary tuberculosis 6 (54.5%) 
Disseminated tuberculosis 4 (36.4%) 
Bone tuberculosis 1 (9.1%) 
Candida infections 9 (8.5%) 
Oral candidiasis 4 (44.4%) 
Candida pneumonia 2 (22.2%) 
Balanitis candida 1 (11.1%) 
Candida sepsis 1 (11.1%) 
Oesophageal candidiasis 1(11.1%) 
Papilloma viral infections 4 (3.8%) 
Vulvovaginal human papilloma 
virus infection 
3 (75%) 
Anogenital warts 1 (25%) 




Cytomegaloviral infections 3 (2.8%) 
Cytomegalovirus mononucleosis 1 (33.3%) 
    Cytomegalovirus viraemia 1 (33.3%) 
Pneumonia cytomegaloviral 1(33.3%) 
Aspergillus infections 1 (0.9%) 
Bronchopulmonary aspergillosis 1 (100%) 
Leprous infections 1 (0.9%) 
Leprosy 1 (100%) 
Infections NEC 1 (0.9%) 






Table 4 reports the frequency of “confirmed non-OI” and “possible/patient 
and/or pathogen- related OI”, after removing 218 infections for which PTs did not 
include a specific pathogen (the complete list of “confirmed non-OI” and 
“possible/patient and/or pathogen- related OI” in supplementary table S2). Among 
the 274 infections classified as “confirmed non-OI, only 59 (21.5%) were related to 
a specific pathogen, while almost in all the infections classified as “possible/patient 
and/or pathogen- related OI” (299/302, 99%), a specific pathogen was identifiable.  
As indicated in table 4, influenza virus, streptococcus, staphylococcus and 
Escherichia resulted the most frequent “non-confirmed OI”. Conversely, for the 
remaining infectious events, classified as “possible/patient and/or pathogen- related 
OI”, the suspicion of an opportunistic condition could be raised for herpes 
infections (193/299, 64.5%) with a different clinical presentation compared to the 
previous group of “confirmed OI”. In particular varicella resulted the most common 
herpes manifestation in this group, affecting 155/299 (51.8%) cases, then followed 
by herpes simplex presentations. Epstein-Barr viral infections were reported in 
38/299 cases (12.7%), generically as infections in 22 cases (7.4%) and classified as 
infectious mononucleosis in 13 cases (4.3%). Latent tuberculosis accounted for 
12/299 (4.1%) cases, followed by few cases of tuberculosis, also with lymph-node 
involvement included in this group. The remaining events of “possible/patient 





Table 4. Frequency of the “confirmed non OI” and “possible/patient and 
pathogen related OI” adjudicated by the SAC after evaluation of the cases available 
in Pharmachild. Clinical presentations were removed because of the lack of the 
specified pathogen. Data are presented as per the MedDRA High Level Term and 
Preferred Term and sorted by frequencies in descending order. 
 







Herpes viral infections, N=193     
Varicella   128 (42.8%) 
Oral herpes   30 (10.1%) 
Varicella zoster virus infection   24 (8.1%) 
Herpes simplex   4 (1.4%) 
Varicella zoster pneumonia   3 (1%) 
Exanthema subitum   1 (0.3%) 
Genital herpes simplex   1 (0.3%) 
Herpes dermatitis   1 (0.3%) 
Ophthalmic herpes simplex   1 (0.3%) 
Epstein-Barr viral infections, N=38     
Epstein-Barr virus infection   22 (7.4%) 
Infectious mononucleosis   13 (4.3%) 
Epstein-Barr viraemia   2 (0.7%) 
Hepatitis infectious mononucleosis   1 (0.3%) 
Tuberculous infections, N=18     
Latent tuberculosis   12 (4.1%) 
Tuberculosis   3 (1%) 
Tuberculosis of intrathoracic lymph nodes   3 (1%) 
Candida infections, N=8     
Vulvovaginal candidiasis   6 (2.1%) 
Anal candidiasis   1 (0.3%) 
Candida infection   1 (0.3%) 
Influenza viral infections, N=14     
Influenza 13 (22%)   
H1N1 influenza 1 (1.7%)   
Streptococcal infections, N=14     




Pharyngitis streptococcal 3 (5.1%)   
Erysipelas 2 (3.4%)   
Pneumonia pneumococcal 2 (3.4%)   
Streptococcal bacteraemia 1 (1.7%)   
Streptococcal infection 1 (1.7%)   
Streptococcal sepsis 1 (1.7%)   
Salmonella infections, N=9     
Gastroenteritis salmonella   6 (2.1%) 
Salmonella bacteraemia   1 (0.3%) 
Salmonellosis   1 (0.3%) 
Typhoid fever   1 (0.3%) 
Molluscum contagiosum viral infections, 
N=7 
    
Molluscum contagiosum   7 (2.3%) 
Cytomegaloviral infections, N=5     
Cytomegalovirus infection   5 (1.7%) 
Campylobacter infections, N=5     
Campylobacter gastroenteritis   5 (1.7%) 
Staphylococcal infections, N=5     
Staphylococcal sepsis 2 (3.4%)   
Furuncle 1 (1.7%)   
Pneumonia staphylococcal 1 (1.7%)   
Toxic shock syndrome staphylococcal 1 (1.7%)   
Escherichia infections, N=4     
Escherichia pyelonephritis 3 (5.1%)   
Cystitis escherichia 1 (1.7%)   
Papilloma viral infections, N=3     
Papilloma viral infection   3 (1%) 
Skin structures and soft tissue infections, 
N=3 
    
Impetigo 3 (5.1%)   
Bordetella infections, N=3     
Pertussis 2 (3.4%)   
Bordetella infection 1 (1.7%)   
Giardia infections, N=3     
Giardiasis   3 (1%) 
Mycoplasma infections, N=3     
Mycoplasma infection 1 (1.7%)   
Pharyngitis mycoplasmal 1 (1.7%)   
Pneumonia mycoplasmal 1 (1.7%)   
Caliciviral infections, N=2     
Gastroenteritis caliciviral 1 (1.7%)   
Gastroenteritis norovirus   1 (0.3%) 
Hepatitis viral infections, N=2     
Hepatitis B   1 (0.3%) 
Hepatitis C   1 (0.3%) 
Parvoviral infections, N=2     
Parvovirus B19 infection   2 (0.7%) 




Gastroenteritis rotavirus   2 (0.7%) 
Yersinia infections, N=2     
Gastroenteritis yersinia 1 (1.7%)   
Yersinia infection 1 (1.7%)   
Blastocystis infections, N=1     
Blastocystis infection 1 (1.7%)   
Bone and joint infections, N=1     
Osteomyelitis acute 1 (1.7%)   
Borrelial infections     
Lyme disease 1 (1.7%)   
Clostridia infections, N=1     
Clostridium difficile colitis 1 (1.7%)   
Coxiella infections, N=1     
Coxiella infection 1 (1.7%)   
Enteroviral infections NEC, N=1     
Enterovirus infection   1 (0.3%) 
Fungal infections NEC, N=1     
Systemic mycosis   1 (0.3%) 
Haemophilus infections, N=1     
Haemophilus infection 1 (1.7%)   
Helicobacter infections, N=1     
Helicobacter gastritis 1 (1.7%)   
Mycobacteria identification and serology, 
N=1 
    
Tuberculin test positive 1 (1.7%)   
Pseudomonal infections, N=1     
Pseudomonal sepsis 1 (1.7%)   
Respiratory syncytial viral infections, N=1     
Respiratory syncytial virus infection   1 (0.3%) 
Rubeola viral infections, N=1     
Pneumonia measles 1 (1.7%)   
 
Discussion 
An evidence based-list of opportunistic pathogens with the related MedDRA 
classification in immunosuppressed children with JIA has been derived by the 
combination of consensus among a panel of pediatricians with expertise in 
rheumatology and infectious diseases, and the analysis of the Pharmachild 
international registry in JIA.(40) The final list of opportunistic 
infections/presentations could constitute a future reference for researchers, 
pharmaceutical companies and regulatory authorities dealing with 




The introduction of biologics in 2000s for the treatment of JIA has dramatically 
changed the prognosis of children affected by JIA, but has also raised concerns on 
the possible risk of infections and other safety events in these patients. Despite the 
widespread use of these drugs, there is still a lack of knowledge regarding the 
assessment of the long-term safety of the biologics in JIA. In this context, the role 
of national and international registries becomes an important source of data.(40;46-
48).   
The international registry Pharmachild has the advantage to combine 
information from different countries based on real clinical data. In Pharmachild 
infections occur in about 11% of patients with JIA(40), and among them it is of 
primary importance to identify the opportunistic ones, that may take advantage of a 
condition of immunosuppression like in children with JIA on therapy. This is not an 
easy task, because apparently there is a great gap between what pediatric 
rheumatologists feel can be considered as an OI and what a panel of experts 
adjudicates as such. While most serious infections occur in the general population, 
some events are more frequent or severe in case of immunosuppression. 
Conversely, some infections, such as tuberculosis, more common in immune 
compromised children, may affect also the general population, although usually less 
severely.(49) Considering these difficulties in correctly defining OI, we made an 
effort to produce a document defining OI specifically in children with JIA on 
immunosuppression, based on the example of a specialized Committee convened in 
the adult setting to define OI in adults with immune mediated diseases on 
biologics.(33) With the same approach, our panel of specialists voted, through a 
three-step Delphi procedure, for a correct definition of definite and probable OI, 
and subsequently produced a list of OI by cross matching the provisional list 
produced by consensus with the Pharmachild data. In a first phase of our study, 
among the Pharmachild patients, a considerable percentage of infections (17.4%) 
was adjudicated as opportunistic. When we matched the provisional list of OI with 
the patients‟ clinical information, it became clear that beside events with full 
agreement between the SAC and the list, which could be considered either 
“confirmed OI” (106/682, 15.5%) or “non-confirmed OI” (274/682, 40.2%), there 




specific patient‟s history and/or the pathogen presentation, and classified as 
“possible/patient and/or pathogen- related OI”. The most explanatory case is 
represented by herpes zoster infection. (Table 3 and 4) While zoster infection was 
included among the “confirmed OI”, as stated in the majority of the literature in this 
issue,(50-52) its clinical presentation varicella, very frequent in our population 
(155/682, 22.7%), due to the high incidence in healthy non vaccinated children and 
its often non complicated presentation, was included among the “possible/patient 
and/or pathogen- related OI”. This group of patients highlights the difficulties in 
defining OIs in JIA children on treatment, but also the critical importance of 
providing a reference document listing those infections that should always be 
considered as opportunistic in these category of patients, with possible implications 
for treatment or prophylaxis.  
The current literature provides similar evidence, but remains controversial for 
the majority of OI. Beukelman et al. in 2012 reviewed US Medicaid data 
comparing the incidence of bacterial infections requiring hospitalization in children 
with and without JIA.(1;31) The infection rate was already twice high in patients 
with JIA not exposed to treatments, compared to children with attention-deficit 
hyperactivity disorder (ADHD) used as controls.(31) The same author one year 
later re-analyzed the same data by comparing the incidence rate of selected OI 
among children with and without JIA. Coccidioides, Salmonella and herpes zoster 
resulted increased in frequency among JIA patients.(30) Among the 15 pathogens 
they used to define their list of OI, all in our provisional OI list (supplementary 
table S1), only Herpes Zoster, Tuberculosis, Pneumocystis and Aspergillus were 
confirmed in our final list of “confirmed OI”. The remaining cases were included in 
the “possible/patient and/or pathogen- related OI” list. Interestingly, the authors 
included primary varicella infection in the OI only if received critical care services 
during the hospitalization. An increased risk of herpes zoster infection was 
confirmed in many studies in literature, both in JIA (50) and in the adult 
rheumatoid arthritis(53). More recently, Aeschlimann et al. studied, through a meta-
analysis, whether treatment with biologics during clinical trial study periods 
increases the risk of serious infections in children with JIA. On a total of 19 trials 




810 children, with bronchopulmonary and varicella being the most frequent 
events.(54) Beside this evidence, the role of other opportunistic pathogens still 
needs to be further investigated.  
 
Conclusions 
In conclusion almost 1/5 of all severe and/or serious infections in JIA patients 
on immunosuppressive therapy are opportunistic. The most frequent opportunistic 
pathogens were herpes virus (excluding non-complicated primary varicella), 
mycobacterial and Candida infections. We provided with our work a list of 
“confirmed OI” in children with JIA on immunosuppressive therapy, that could be 
used as possible reference document for future works on pharmacovigilance in 
children with JIA on immunosuppressive therapy, and a list of infections that could 
possibly display an opportunistic nature related to the patient‟s history and/or the 
pathogen presentation. More clarity in the understanding of OI in JIA children on 
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Table S1. Provisional list of pathogens/presentations and MedDRA HLT term 
approved by consensus by the SAC. Highlighted in red those 
pathogens/presentations modified by the SAC after consensus and literature review 




DEFINITION OF DEFINITE OPPORTUNISTIC INFECTION 
IN JIA CHILDREN 
HLT 
1. Generally does not occur in the absence of immunosuppression and 
whose presence suggests a severe alteration in host immunity  OR 
 
2. Can occur in patients without recognized forms of 
immunosuppression, but whose presence indicates a potential or likely 
alteration in host immunity  
 
List of definite pathogens and/or presentations of specific 
pathogens  
 
Aspergillosis (invasive disease only)  Aspergillus infections 
Bartonellosis (disseminated disease only)  Bartonella infections 
BK virus disease including PVAN  BK virus infection 
Blastomycosis  Blastomyces infections 





Cryptococcosis   Cryptococcal infections 
Cytomegalovirus disease with onset at age > 1 month: pneumonia 
(CMV in BAL), colitis, CNS disease (CMV in CSF), liver (biopsy), 




HBV reactivation  Hepatitis viral infections 
Herpes simplex (invasive disease only)  Herpes viral infections 
Herpes zoster (any form)  Herpes viral infections 
Histoplasmosis  Histoplasma infections 
Legionellosis  Legionella infections 
Listeria monocytogenes (invasive disease only)  Listeria infections 




Non-tuberculous mycobacterium disease  
Atypical mycobacterial 
infections 
Other invasive fungi: Mucormycosis (zygomycosis) (Rhizopus, Mucor 
and Lichtheimia), Scedosporium /Pseudallescheria boydii, Fusarium  
Fungal infections NEC 
Pneumocystis jirovecii  Pneumocystis infections 
Post-transplant lymphoproliferative disorder (EBV) 
Epstein-Barr viral 
infections 
Progressive multifocal leucoencephalopathy Polyomavirus infections 
Salmonellosis (invasive disease only)  Salmonella infections 
Strongyloides (hyperinfection syndrome and disseminated forms only)  Nematode infections 
Toxoplasmosis of central nervous system, onset at age ≥ 1 month; 
Disseminated toxoplasmosis, visceral toxoplasmosis 
Toxoplasma infections 
Tuberculosis  Tuberculous infections 
DEFINITION OF PROBABLE OPPORTUNISTIC INFECTION  
Published data is currently lacking, but expert opinion believes that 
risk is likely elevated in the setting of biologic therapy. In case of the 
unusually severe course of infection due to a common pathogen with 
usually mild disease the pathogen might tentatively be considered 
opportunistic in a patient with impaired immune function. Below there 
is a non-exhaustive list of possible pathogens  
 
List of probable pathogens and/or presentations of specific 
pathogens  
 
Campylobacteriosis (invasive disease only) 
Campylobacter 
infections 
Cryptosporidium species (chronic disease only) 
Cryptosporidia 
infections 
Enterovirus chronic encephalitis 
Enteroviral infections 
NEC 
Giardia, Isospora: chronic (>1 month) diarrhea  
Giardia infections/ 
Isospora infections 
HCV progression  Hepatitis viral infections 
Human Herpes Virus (HHV6-7): pneumonia, encephalitis Herpes viral infections 
Human Herpes Virus (HHV8): kaposi sarcoma  Herpes viral infections 
Human metapneumovirus (hMPV): pneumonia, ARDS  Viral infections NEC 
Human Papilloma Virus (HPV): extensive warts  
Papilloma viral 
infections 
Human respiratory syncytial virus (RSV): pneumonia with onset > 6 






Legionellosis  Legionella infections 




Molluscum contagiosa: chronic, disseminated  
Molluscum contagiosum  
Paracoccidioides infections  
Paracoccidioides 
infections 
Parvovirus B19: pure red cell aplasia Parvoviral infections 
Penicillium marneffei Fungal infections NEC 




Shigellosis (invasive disease only)  Shigella infections 
Sporothrix schenckii  Sporothrix infections 
Trypanosoma cruzi infection (Chagas‟ disease) (disseminated disease 
only)  
Trypanosomal infections 
Varicella: encephalitis (excluding cerebellitis), hepatitis, pneumonia  Herpes viral infections 
Vibriosis (invasive disease due to Vibrio vulnificus)  Vibrio infections 






Supplementary Table S2. Complete table with the frequency of the 682 infections adjudicated by the SAC after evaluation of the cases 
available in Pharmachild compared to the pathogens/presentations in the provisional list approved by the SAC. Data are presented as per 
the MedDRA High Level Term (HLT) and Preferred Term (PT) sorted by frequencies in descending order (HLT and then PT). *For the 
definition see Step 5. 
 
HLT-PT NAME N % 
“Confirme







Herpes viral infections 265 38.9%    
Varicella 128 48.3%   x 
Herpes zoster 66 24.9% x   
Oral herpes 30 11.3%   x 
Varicella zoster virus infection 24 9.1%   x 
Herpes simplex 4 1.5%   x 
Varicella zoster pneumonia 3 1.1%   x 
Herpes ophthalmic 2 0.7% x   
Exanthema subitum 1 0.4%   x 
Genital herpes simplex 1 0.4%   x 
Herpes dermatitis 1 0.4%   x 
Herpes virus infection 1 0.4% x   
Herpes zoster oticus 1 0.4% x   
Ophthalmic herpes simplex 1 0.4%   x 




HLT-PT NAME N % 
“Confirme







Lower respiratory tract and lung infections 49 7.2%    
Pneumonia 41 83.6%  x  
Atypical pneumonia 2 4.1%  x  
Bronchitis 2 4.1%  x  
Infectious pleural effusion 2 4.1%   x 
Lower respiratory tract infection 2 4.1%  x  
Upper respiratory tract infections 44 6.4%    
Upper respiratory tract infection 14 31.8%  x  
Tonsillitis 11 25%  x  
Pharyngitis 8 18.2%  x  
Sinusitis 3 6.8%  x  
Chronic sinusitis 2 4.5%  x  
Pharyngotonsillitis 2 4.5%  x  
Rhinitis 2 4.5%  x  
Adenoiditis 1 2.3%  x  
Laryngitis 1 2.3%  x  
Epstein-Barr viral infections 38 5.6%    
Epstein-Barr virus infection 22 57.9%   x 
Infectious mononucleosis 13 34.2%   x 
Epstein-Barr viraemia 2 5.3%   x 
Hepatitis infectious mononucleosis 1 2.6%   x 
Abdominal and gastrointestinal infections 32 4.7%    




HLT-PT NAME N % 
“Confirme







Appendicitis 12 37.5%  x  
Appendicitis perforated 3 9.4%  x  
Anal abscess 1 3.1%  x  
Gastrointestinal infection 1 3.1%  x  
Tuberculous infections 29 4.2%    
Latent tuberculosis 12 41.4%   x 
Pulmonary tuberculosis 6 20.7% x   
Disseminated tuberculosis 4 13.8% x   
Tuberculosis 3 10.3%   x 
Tuberculosis of intrathoracic lymph nodes 3 10.3%   x 
Bone tuberculosis 1 3.4% x   
Bacterial infections NEC 27 4%    
Pneumonia bacterial 11 40.8%  x  
Cellulitis 2 7.4%  x  
Nail bed infection bacterial 2 7.4%  x  
Upper respiratory tract infection bacterial 2 7.4%  x  
Urinary tract infection bacterial 2 7.4%  x  
Wound infection bacterial 2 7.4%  x  
Ear infection bacterial 1 3.7%  x  
Lymphadenitis bacterial 1 3.7%  x  
Otitis externa bacterial 1 3.7%  x  
Peritonitis bacterial 1 3.7%  x  




HLT-PT NAME N % 
“Confirme







Pyomyositis 1 3.7%  x  
Infections NEC 21 3.1%    
Respiratory tract infection 12 57.1%  x  
Abscess limb 2 9.5%  x  
Postoperative wound infection 2 9.5%  x  
Wound infection 2 9.5%  x  
Infection in an immunocompromised host 1 4.8% x   
Injection site infection 1 4.8%  x  
Lymph node abscess 1 4.8%  x  
Ear infections 18 2.6%    
Otitis media acute 8 44.4%  x  
Otitis media 5 27.7%  x  
Ear infection 3 16.7%  x  
Otitis externa 1 5.6%  x  
Otitis media chronic 1 5.6%  x  
Candida infections 17 2.5%    
Vulvovaginal candidiasis 6 35.3%   x 
Oral candidiasis 4 23.5% x   
Candida pneumonia 2 11.7% x   
Anal candidiasis 1 5.9%   x 
Balanitis candida 1 5.9% x   
Candida infection 1 5.9%   x 




HLT-PT NAME N % 
“Confirme







Oesophageal candidiasis 1 5.9% x   
Influenza viral infections 14 2.1%    
Influenza 13 92.9%  x  
H1N1 influenza 1 7.1%  x  
Streptococcal infections 14 2.1%    
Scarlet fever 4 28.6%  x  
Pharyngitis streptococcal 3 21.4%  x  
Erysipelas 2 14.3%  x  
Pneumonia pneumococcal 2 14.3%  x  
Streptococcal bacteraemia 1 7.1%  x  
Streptococcal infection 1 7.1%  x  
Streptococcal sepsis 1 7.1%  x  
Salmonella infections 9 1.3%    
Gastroenteritis salmonella 6 66.7%   x 
Salmonella bacteraemia 1 11.1%   x 
Salmonellosis 1 11.1%   x 
Typhoid fever 1 11.1%   x 
Urinary tract infections 9 1.3%    
Pyelonephritis 5 55.6%  x  
Urinary tract infection 2 22.2%  x  
Cystitis 1 11.1%  x  
Pyelonephritis acute 1 11.1%  x  




HLT-PT NAME N % 
“Confirme







Cytomegalovirus infection 5 62.5%   x 
Cytomegalovirus mononucleosis 1 12.5% x   
Cytomegalovirus viraemia 1 12.5% x   
Pneumonia cytomegaloviral 1 12.5% x   
Molluscum contagiosum viral infections 7 1.1%    
Molluscum contagiosum 7 100%   x 
Papilloma viral infections 7 1.1%    
Papilloma viral infection 3 42.8%   x 
Vulvovaginal human papilloma virus 
infection 
3 42.8% x 
  
Anogenital warts 1 14.4% x   
Sepsis, bacteraemia, viraemia and fungaemia 
NEC 
7 1.1%  
  
Device related sepsis 2 28.6%  x  
Sepsis 2 28.6%  x  
Sepsis syndrome 2 28.6%  x  
Viraemia 1 14.3%   x 
Campylobacter infections 5 0.7%    
Campylobacter gastroenteritis 5 100%   x 
Staphylococcal infections 5 0.7%    
Staphylococcal sepsis 2 40%  x  
Furuncle 1 20%  x  




HLT-PT NAME N % 
“Confirme







Toxic shock syndrome staphylococcal 1 20%  x  
Viral infections NEC 5 0.7%    
Viral upper respiratory tract infection 3 60%  x  
Gastroenteritis viral 2 40%  x  
Escherichia infections 4 0.6%    
Escherichia pyelonephritis 3 75%  x  
Cystitis escherichia 1 25%  x  
Pneumocystis infections 4 0.6%    
Pneumocystis jirovecii pneumonia 4 100% x   
Skin structures and soft tissue infections 4 0.6%    
Impetigo 3 75%  x  
Subcutaneous abscess 1 25%  x  
Bordetella infections 3 0.4%    
Pertussis 2 66.7%  x  
Bordetella infection 1 33.3%  x  
Dental and oral soft tissue infections 3 0.4%    
Tooth abscess 2 66.7%  x  
Sialoadenitis 1 33.3%  x  
Giardia infections 3 0.4%    
Giardiasis 3 100%   x 
Mycoplasma infections 3 0.4%    
Mycoplasma infection 1 33.3%  x  




HLT-PT NAME N % 
“Confirme







Pneumonia mycoplasmal 1 33.3%  x  
Caliciviral infections 2 0.3%    
    Gastroenteritis caliciviral 1 50%  x  
    Gastroenteritis norovirus 1 50%   x 
Eye and eyelid infections 2 0.3%    
Conjunctivitis 2 100%  x  
Hepatitis viral infections 2 0.3%    
Hepatitis B 1 50%   x 
Hepatitis C 1 50%   x 
Parvoviral infections 2 0.3%    
Parvovirus B19 infection 2 100%   x 
Rotaviral infections 2 0.3%    
Gastroenteritis rotavirus 2 100%   x 
Yersinia infections 2 0.3%    
Gastroenteritis yersinia 1 50%  x  
Yersinia infection 1 50%  x  
Aspergillus infections 1 0.1%    
Bronchopulmonary aspergillosis 1 100% x   
Blastocystis infections 1 0.1%    
Blastocystis infection 1 100%  x  
Bone and joint infections 1 0.1%    
Osteomyelitis acute 1 100%  x  




HLT-PT NAME N % 
“Confirme







Lyme disease 1 100%  x  
Clostridia infections 1 0.1%    
Clostridium difficile colitis 1 100%  x  
Coxiella infections 1 0.1%    
Coxiella infection 1 100%  x  
Enteroviral infections NEC 1 0.1%    
Enterovirus infection 1 100%   x 
Fungal infections NEC 1 0.1%    
Systemic mycosis 1 100%   x 
Haemophilus infections 1 0.1%    
Haemophilus infection 1 100%  x  
Helicobacter infections 1 0.1%    
Helicobacter gastritis 1 100%  x  
Leprous infections 1 0.1%    
Leprosy 1 100% x   
Muscle and soft tissue infections 1 0.1%    
Psoas abscess 1 100%  x  
Mycobacteria identification and serology 1 0.1%    
Tuberculin test positive 1 100%  x  
Pseudomonal infections 1 0.1%    
Pseudomonal sepsis 1 100%  x  
Respiratory syncytial viral infections 1 0.1%    




HLT-PT NAME N % 
“Confirme







Rubeola viral infections 1 0.1%    
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